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Abstract 
 
The intestinal epithelium is one of the fastest renewing tissues within the adult. This renewal is 
primarily driven by the intestinal epithelial stem cell compartment and homeostasis of this 
compartment needs to be strictly maintained. Loss of regulation can lead to hyperplasia and 
subsequent malignant transformation. Moreover, cancers are also thought to contain a stem cell 
population which maintains long term tumor viability and recurrence following therapy. 
Therefore, a thorough understanding of the molecular machinery that governs stem cell 
homeostasis can further our understanding of colon cancer initiation and progression. The RNA 
binding protein RBM3 is upregulated in many solid tumors including colon, prostate and breast. 
It also serves as a proto-oncogene inducing the malignant transformation of normal cells when 
overexpressed. To further characterize the mechanism, we overexpressed RBM3 in DLD-1 and 
HCT 116 colon cancer cell lines. We show that RBM3 overexpression is capable of increasing 
the cancer stem cell phenotype as measured by side population assay, spheroid formation and 
expression of the putative stem cell markers DCLK1, LGR5 and CD44. Interestingly, RBM3 
also increases chemoresistance through increased multidrug efflux and quiescence, both 
characteristics commonly attributed to cancer stem cells. Moreover, RBM3 overexpression 
appears to increase activity of the β-catenin signaling cascade, a pathway critical for the 
maintenance of stem cell self-renewal and implicated in the pathogenesis of colon cancer. We 
also show that RBM3 overexpression decreases the activity of GSK3β, a member of the 
destruction complex known to suppress β-catenin levels within the cell. Consistent with this, 
pharmacologic inhibition of GSK3β similarly phenocopies RBM3 induced β-catenin 
transcriptional activity. Taken together, we conclude that RBM3 overexpression is capable of 
iv 
 
increasing the cancer stem cell population. We also show a novel role for RBM3 in increasing β-
catenin signaling activity. Based on these data, we infer that the overexpression of RBM3 
observed within solid tumors may be critical for maintaining self-renewal within the cancer stem 
cells and necessary for long term viability of tumor formation. 
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Intestinal epithelial renewal 
The intestinal epithelium is one of the fastest renewing tissues in adult mammals (Heath, 1996). 
It is composed of a one cell thick layer of epithelial cells that serves the functions of nutrient and 
water absorption, mucous secretion, and barrier formation. This epithelial layer is turned over 
approximately every three to four days and requires a high rate of proliferation to maintain this 
rate of turnover. Small shifts in the proliferative rate can result in significant changes to normal 
intestinal function and hence disease. A decrease in intestinal epithelial renewal may result in 
wasting disease or loss of intestinal barrier function, and more importantly, hyperplastic 
proliferation can result in the formation of intestinal malignancies. As such, intestinal epithelial 
renewal needs to be tightly regulated. It is important to understand the signaling pathways that 
regulate intestinal epithelial renewal and in turn the factors that can influence the activity of 
these signaling pathways in order to further understand the pathogenesis and mechanisms of 
disease states such as colorectal cancer.  
This study is primarily focused on stem cells as they relate to colon cancer. We begin this 
discussion with an overview of the current knowledge of the stem cell in the context of normal 
adult intestinal physiology and progress into implications of this evidence in the study of cancer.  
 
Intestinal epithelial architecture, hierarchy and the intestinal stem cell 
The intestinal epithelial layer is composed of crypts of Lieberkühn which are invaginations of the 
intestinal surface, and villi which are protrusions of the intestinal surface (Figure 1). This surface 
from the crypt base to the villus apex composes the crypt-villus axis. The majority of 
proliferation occurs at a proliferative zone near the crypt base called the transit amplifying 
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Figure 1: Schematic diagram of the crypt-villus axis of the small intestine. 
Depicted are the +4 LRC, the CBC and the transit amplifying compartment. 
Additionally, intensity of the Wnt/β-catenin signaling cascade is represented on 
the left. The colon differs from the small intestine in that there are no villi, the 
goblet cells are present in greater abundance and paneth cells are absent.  
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compartment. Cells reside within this region for approximately two days dividing several times, 
then terminally differentiate into one of three lineages: enterocyte, goblet cell or enteroendocrine 
cell and ascend along the crypt-villus axis for approximately three days until undergoing 
spontaneous apoptosis at or near the villus apex (Hall et al., 1994). There is also one 
differentiated cell type – the paneth cell – which resides at the crypt bottom. Additionally there 
are a few differences between the architecture of the large and small intestine. Notably, relative 
to the small intestine, the large intestine has no villus structures, the proportion of mucus 
secreting goblet cells is significantly increased and the crypt bases contain no paneth cells.  
In order to understand the driving force of intestinal renewal, it was shown that at the bases of 
crypts exist a small population of intestinal stem cells (ISCs) through several different studies. 
One of the original studies illustrated that the entire epithelium of each crypt clonal in origin. 
Using immunohistochemistry (IHC) to measure glucose-6-phosphate dehydrogenase (G6PDH) 
activity in mice with a heterozygous mutation for G6PDH following treatment with a colonic 
mutagen, it was revealed that loss of heterozygosity (LOH) occurred across entire crypts 
(Griffiths et al., 1988). This finding rather than sporadic LOH along crypts implied that the 
epithelial lining of crypts arose in a clonal fashion. Additionally, by observing crypts of chimeric 
mice, it was observed that crypts originate as polyclonal structures, but over time, become 
monoclonal (Schmidt et al., 1988). These studies imply that the entire epithelium of each 
intestinal crypt must arise from a very limited number of cells residing within the crypt that give 
rise to a clonal population of differentiated epithelial cells. 
Stem cells are cells with the capacity to give rise to differentiated cell lineages and the capacity 
to generate at least one daughter cell that maintains the stem cell phenotype (self-renewal) 
(Wagers and Weissman, 2004). Indeed in the intestinal crypt two discrete populations of cells 
5
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have been elucidated which both have the capacity to self-renew and which generate the full 
spectrum of differentiated intestinal epithelial lineages. However, these two populations are 
characterized with distinct niches and different proliferative capacity. The first identified 
population was observed through label retention studies. Potten, et al. demonstrated that 
following treatment with a nucleoside analogue, there was a small population of cells near the 
base of the crypt that retained the nucleoside label for up to four weeks (Potten et al., 1978). 
These cells referred to as label retaining cells (LRCs) are located approximately four cells from 
the base of the crypt in the supra-paneth region also known as the +4 position. The +4 LRC 
represents a subpopulation of quiescent stem cells within the crypt (Potten et al., 1997). These 
LRCs are also insensitive to inactivation of CDC25 (a protein required to drive cell cycle 
progression) further suggesting that the LRCs represent a quiescent stem cell pool (Lee et al., 
2009).  
More recently discovered is the population of crypt basal columnar cells (CBCs) that lie at the 
very base of the crypt. CBCs were originally described as a cycling population of cells residing 
between paneth cells within the base of the crypt (Cheng and Leblond, 1974). They are also 
morphologically distinct from the +4 LRCs as they are interspersed between paneth cells, contain 
very little cytoplasm and have a sliver-like shape (Barker et al., 2007). Additionally, CBCs 
harvested through laser capture microdissection have been shown to share gene signatures with 
hematopoietic stem cells (HSCs) and neural stem cells (Stappenbeck et al., 2003). Later studies 
showed that these cells represent a long lived but rapidly cycling ISC pool that is capable of 
generating the differentiated epithelial lineages (Barker et al., 2007). In contrast to LRCs, CBCs 
are indeed sensitive to loss of CDC25 and show loss of cell cycle progression and differentiation 
following CDC25 deletion (Lee et al., 2009). Finally, it was shown that the CBC population isn’t 
 
strictly necessary for maintaining intestinal epithelial homeostasis (Tian et al., 2011). In fact, 
diphtheria toxin directed ablation of the CBC compartment was compensated for by expansion of 
the +4 LRC population which later regenerated the CBC population. This study provides 
evidence for a hierarchical relationship with the quiescent +4 LRC giving rise to the rapidly 
cycling CBC (Tian et al., 2011). On the other hand, +4 LRCs have been shown to be especially 
susceptible to radiation based injury, presumably to protect the genomic integrity of the cell 
responsible for producing the entire progeny of the crypt (May et al., 2008; Potten, 1977). CBCs 
on the other hand, have been shown to be indispensable for crypt regeneration following 
radiation injury, implying that +4 LRCs undergo apoptosis more readily in the context of 
genotoxic injury, at which point CBCs can serve as the reserve population for the +4 LRCs 
(Metcalfe et al., 2013). Current evidence suggests that the CBC and LRC populations serve to 
compensate for loss of eachother under certain contexts, however the exact role that each distinct 
stem cell population plays in maintaining intestinal epithelial homeostasis and oncogenic 
transformation as well as the interplay between the quiescent and rapidly cycling stem cell pool 
is not yet fully understood. 
In order to further characterize the functional roles of these distinct ISC populations, large efforts 
have been made to identify and isolate LRCs and CBCs. Concomitantly with the studies that 
revealed some of the functional roles and niches of the LRCs and CBCs, studies were conducted 
which revealed specific markers for these populations. One of the initially identified stem cell 
markers of the LRC population was B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) 
(Sangiorgi and Capecchi, 2008). Bmi-1 was originally found to be an important regulator of the 
proliferation of HSCs as well as a marker of neural stem cells (Lessard and Sauvageau, 2003; 
Molofsky et al., 2003). Later studies showed that Bmi-1 also marks the +4 LRC and that these 
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cells were capable of self-renewal and differentiation as demonstrated by their ability to generate 
the four lineages of the small intestine. A Bmi-1 specific expression of diphtheria toxin receptor 
results in crypt degeneration following administration of diphtheria toxin (Sangiorgi and 
Capecchi, 2008). This observation serves to further validate the stem cell properties of the +4 
LRC as well as implicates Bmi-1 expression as a marker of the LRC. Additionally, one of the 
more recently discovered markers of the LRC is doublecortin containing calmodulin-like kinase 
1 (DCLK1) which is expressed in discrete cells at the +4 position in the intestinal crypt 
(Giannakis et al., 2006; May et al., 2008).  
A potential stem cell marker known to identify cells of the CBC niche is the Leucine-rich repeat-
containing G-protein coupled receptor 5 (LGR5). LGR5 was first identified as a target of the 
Wnt/β-catenin pathway that is highly upregulated at the crypt base. Additionally, lineage tracing 
experiments using the LGR5 promoter to activate LacZ expression showed discrete clonal 
ribbons of LacZ positive cells implying that LGR5 positive cells could generate a crypt of clonal 
origin with all four differentiated epithelial lineages (Barker et al., 2007). A more in depth 
discussion on the relation between these stem cell markers and intestinal tumorigenesis is 
discussed in the following section. 
There are however, some largely important questions arising when investigating these stem cell 
markers. First, are these markers truly markers of stem cells or are they just upregulated in stem 
cells leading to and enrichment rather than a distinctive marking of stem cells? Additionally, 
while many stem cell markers have been elucidated, it is unclear what their functional relevance 
is in the stem cell. The question remains whether expression of these markers can induce or 
maintain the stem cell phenotype or if the stem cell phenotype leads to expression of these 
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markers. While these questions remain largely outside of the scope of the current study, they are 
an important aspect of ISC physiology that warrants investigation. 
 
Cancer stem cells 
The cancer stem cell (CSC) is a cell type with similar properties to physiologic stem cells with 
the capacity to self-renew (usually measured as capacity to generate long lived tumors), the 
capacity to differentiate (usually measured as the capacity to generate phenotypically distinct 
progeny) and generally considered to have the capacity to initiate tumor formation. The CSC 
model necessitates a hierarchical relationship within the tumor where CSCs generate progeny 
that proliferate and to a limited extent differentiate. Early evidence for this paradigm comes from 
observations that the proliferative index of tumors is inversely correlated with the degree of 
differentiation of the tumor cells and that clonal markers of cancer initiation appear within 
multiple cell lineages (Buick and Pollak, 1984; Fialkow et al., 1977). 
The first isolation of the cancer stem cell (CSC) population was demonstrated by Lapidot, et al. 
using mouse acute myeloid leukemia (AML) cells. It was observed that cells positive for CD34 
and negative for CD38 (CD34+/CD38-) made up a small fraction of the overall population of 
leukemia cells, however, isolation of this small cell population and transplantation into severe 
combined immune deficient (SCID) mice resulting in recapitulation of the original AML 
containing the differentiated spectrum of tumor cells (Lapidot et al., 1994). Importantly, the 
recapitulation of the tumor was established using far fewer seeding cells implying that there is a 
very limited portion of cells within a given neoplasm that are capable of initiating tumor 
formation. This study also implied that the stem cell hierarchy is not only relevant in the 
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physiologic context, but tumors may also subscribe to a hierarchy where CSCs give rise to 
proliferative progeny that make up the bulk of the tumor.  
Tumor initiating cells have been demonstrated in a number of other solid tumors including breast 
and colon. For example, cells from primary breast cancers were examined for cell surface marker 
expression and it was found that cells with the CD44+/CD24Lo/Lineage- phenotype were capable 
of initiating tumors in xenografts while alternate phenotypes yielded no significant tumor 
initiating capacity (Al-Hajj et al., 2003). These studies also showed that the tumors recapitulated 
by the CD44+/CD24Lo/Lineage- were capable of generating heterogenous tumors, implying 
capacity to differentiate, and long lived tumors, implying capacity to self-renew. In contrast to 
this work, additional studies suggest that the CD44+/CD24+/ESA+ cell population may be the 
stem cell population in pancreatic tissue (Li et al., 2007). 
As a loss of homeostasis of the stem cell population is thought to be responsible for the initiation 
of some tumors, it is important to understand the concepts underlying stem cell compartment 
expansion. Generally speaking, there are two primary routes to increasing the stem cell 
population. First, regulation pathways within existing stem cells could cease to function 
adequately, as in the case of overactivation of the Wnt/β-catenin pathway, which results in 
increased symmetric divisions. Under the conditions of symmetric divisions, both daughter cells 
retain an undifferentiated state with stem cell characteristics (Figure 2). It has been demonstrated 
that under physiologic conditions, the majority of ISC divisions are asymmetric divisions giving 
rise to a single stem daughter cell and one daughter cell fated to terminally differentiate with a 
small portion of stem cell divisions being symmetric divisions. Using epigenetic methylations 
signatures for individual human colon crypts, Yakiba et al. deduced that ISCs undergo 
asymmetric divisions approximately 95% of the time with the expression and increased divisions 
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Figure 2: Diagrammatic representation of the expansion of the stem cell 
compartment resulting in increase in proliferative progeny. Left is a 
representation of asymmetric division giving rise proliferative progeny. Right is 
dysregulation of stem cell homeostasis resulting in increased stem cell population 
and increased proliferative progeny. 
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or spontaneous extinction of the stem cell (Yatabe et al., 2001). Presumably the small percentage 
of symmetric divisions allows for crypt fission to regenerate lost neighboring crypts due to 
degeneration of injury.  
Second, it is possible that cells fated to terminally differentiate retain some amount of plasticity 
and, due to dysregulated signaling pathways, undergo dedifferentiation where they reacquire 
stem cell characteristics. In support of this, it was recently shown that by overexpressing an 
inflammatory signaling mediator, NFκB, and inducing a secondary effect of Wnt activation, non-
stem cells within the crypt were capable of dedifferentiating to stem-like cells with tumor 
initiating characteristics (Schwitalla et al., 2013). This concept of cellular plasticity and 
dedifferentiation implies that the stem cell to progenitor cell hierarchy is in fact not 
unidirectional but rather bidirectional with progenitor cells retaining a limited capacity to acquire 
stem cell properties.  
These studies demonstrate that the CSC is an important part of the regulation of cancer in 
general. Also, it is currently poorly understood how CSCs can serve a role in initiating malignant 
progression. It is possible that only ISCs that have become dysregulated are capable of malignant 
transformation, or it is possible that ISC progeny can display a limited capacity to dedifferentiate 
and attain cancer initiating properties. 
 
Stem cell markers for CSCs 
In order to further understand roles of CSCs in cancer initiation and progression, several stem 
cell markers have been implicated with the CSC phenotype. Recent studies have demonstrated 
that the ISC markers LGR5 and DCLK1 serve major roles in colon cancer pathogenesis. For 
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example, using the LGR5 promoter driven deletion of the tumor suppressor adenomatous 
polyposis coli (APC) showed that LGR5-positive cells with loss of the tumor suppressing effects 
of APC leads to malignant transformation within days and generate long lived adenomas with 
unimpeded growth over weeks (Barker et al., 2009). On the other hand, APC deletion in transit 
amplifying cells showed adenoma formation that rapidly stalled. These studies suggest that loss 
of appropriate stem cell signaling in the physiologic ISC is a driving factor behind intestinal 
tumorigenesis. It also suggests that the progeny of ISCs fated to terminally differentiate have 
limited capacity to initiate malignant transformation and maintain tumor formation as they have 
limited self-renewal capacity. 
A similar study crossing a well-established genetic mouse model for colon cancer, the APCMin/+ 
mouse, with a DCLK1 promoter driven LacZ lineage tracer revealed that adenoma formation 
within the mouse intestine originated from a DCLK1-positive CSC (Nakanishi et al., 2013). 
Interestingly, the parallel experiment using LGR5 lineage tracing in APCMin/+ mouse showed 
most of the normal intestine showed LacZ expression with focally higher expression within 
adenomas. Most importantly, DCLK1 promoter driven diphtheria toxin receptor expression 
combined with treatment with diphtheria toxin in APCMin/+ showed significant ablation of 
adenoma formation. These studies demonstrate that tumors of the intestine have a high likelihood 
of forming from the ISC and that DCLK1 positive cells may play a more significant role in 
tumorigenesis rather than normal intestinal function. Additional studies have implicated DCLK1 
as a stem cell marker and potential marker for CSCs in pancreatic cancer, neuroblastoma and 
gastric cancer (May et al., 2010; Qing-Bin et al., 2013; Sureban et al., 2011; Verissimo et al., 
2012).  
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While LGR5 and DCLK1 were discovered based upon functional aspects of the ISCs and then 
validated as markers for CSCs, there are numerous other markers that have been shown to mark 
colonic CSCs with variable reliability. The enzyme aldehyde dehydrogenase 1A1 (ALDH1A1) 
was a promising stem cell marker in numerous epithelial tissues. Strongly ALDH1A1 positive 
cells were seen in the putative ISC niche while the remaining colon crypt was weakly ALDH1 
positive (Deng et al., 2010). Additionally, high levels of nuclear localized ALDH1A1 as 
measured by IHC has been shown to predict shortened overall survival while increased 
cytoplasmic staining showed no association with prognosis (Kahlert et al., 2012). 
Another potential stem cell marker for neuronal stem cells was identified in 2000 by Uchida, et 
al. In this study it was shown that human neuronal cells expressing a phenotype of CD133+, 
CD34-, CD45- were capable of enhanced neurosphere formation, a property thought to be a 
characteristic of stem cells. Additionally, CD133+/CD34-/CD45- cells showed the capacity to 
differentiate into neurons or glia, and could self-renew producing secondary neurospheres 
(Uchida et al., 2000). The relevance of CD133 in colorectal cancer was elucidated with a study 
showing that CD133+ colon cancer cells, while only comprising a minority of the total cell 
population, were able to increase tumor initiation capacity from 1/57,000 to 1/262. The CD133+ 
cells were able to reconstitute a heterogeneous population of cells within tumor xenografts and 
were able to self-renew giving rise to secondary tumors (O'Brien et al., 2007). Additionally, it 
was recently shown that membrane expression levels of CD133 significantly correlated with 
chemoresistance and recurrence of colorectal cancer following surgical intervention (Takahashi 
et al., 2010). On the other hand, recent studies have also shown that CD133- cells taken from 
metastases are also capable of initiating tumor formation and sustaining long term tumors in a 
xenograft casting some doubt regarding the reliability of CD133 as a stem cell marker 
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(Shmelkov et al., 2008). There is currently some controversy regarding CD133 as a stem cell 
marker with some studies showing that CD133+ cells are required for tumor initiation and others 
claiming that tumor initiation can be accomplished by CD133- cells. It is possible that certain 
molecular mechanisms result in a CD133+ stem cell in specific cancers while other cancers 
contain CSCs that do not express CD133. However, the relevance of CD133 expression and 
CSCs is currently under debate. 
Another stem cell marker, CD44 has shown significant promise as it marks cells that can be 
more aggressive and metastatic. In immortalized non-transformed breast epithelial cells, it was 
shown that cells expressing high levels of CD44 and low levels of CD24 (CD44+/CD24Lo) 
displayed increased mammosphere formation (Al-Hajj et al., 2003). Interestingly, these cells also 
showed a more mesenchymal phenotype (Mani et al., 2008). These studies indicated that the 
combination of CD44+/CD24Lo phenotype would select for a more mesenchymal cell and that the 
mesenchymal cells are enriched for stem cells at least in breast cancers. In colorectal cancer, 
cells displaying a CD44+ phenotype also showed increased tumor initiating capacity, increased 
capacity for differentiation as observed by their capacity to regenerate a heterogenous tumor and 
increased self-renewal as shown by their capacity to generate long term tumor xenografts 
(Dalerba et al., 2007). However, the relative enrichment of CD44+ cells for stem cells and the 
relevance of CD44 or CD133 as stem cell markers has been questioned by a number of recent 
studies (Muraro et al., 2012; Wang et al., 2012). 
Overall, there are a number of CSC markers for several different tissues. However, it should be 
noted that studies regarding stem cell markers are numerous and differing in their views of the 
reliability of said markers. Because of many of the robust in vivo studies demonstrating the 
effects of DCLK1 and LGR5 in ISCs, in the current study, we primarily investigate changes in 
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DCLK1 and LGR5 as markers of the stem cell phenotype. Additionally due to relations with the 
Wnt/β-catenin signaling pathway, we will also investigate utilize the CD44/CD24 phenotype to 
measure “stemness.” 
 
CSCs and resistance to treatment 
The importance of the CSC cannot be emphasized enough. One of the major properties of the 
CSC is that it’s relatively resistance to conventional chemotherapies. Often, chemotherapy 
regimens result in early tumor regression followed by late tumor relapse. These relapsed tumors 
can be composed of a chemoresistant population that is refractory to a second round of treatment. 
It is estimated that greater than 90% of chemotherapy failures in metastatic disease is due to the 
acquisition of chemoresistance (Longley and Johnston, 2005). Current evidence supports a few 
paradigms leading to chemoresistant recurrence of tumors (Meacham and Morrison, 2013). One 
possibility is that if the tumor contains enough genetic diversity, some existing mutation allows 
for the continued propagation of subclones of the tumor. This is evidenced by the fact that 
following chemotherapy of some acute myelocytic leukemias previously minor subclones 
become dominant implying a genetic advantage of this subclone either during or following 
therapy (Ding et al., 2012; Meacham and Morrison, 2013). Another possibility is that 
chemotherapies allow a subset of the heterogeneous tumor population to survive and given 
enough time, de novo mutations occur allowing for a subclone to escape from the cytostatic or 
cytotoxic effects of chemotherapy. For example, imatinib is a tyrosine kinase inhibitor that 
targets Bcr-Abl, a tyrosine kinase often observed in chronic myeloid leukemia. Imatinib 
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resistance can often be traced to secondary mutations in the BCR-ABL gene resulting in relapse 
(Bixby and Talpaz, 2011; Meacham and Morrison, 2013).  
The model primarily investigated within this study is that that tumor relapse occurs through 
survival of the chemoresistant CSC population following the initial round of therapy. This CSC 
population could then later gives rise to a rapidly dividing pool of chemoresistant progeny 
(Figure 3). While this model cannot be generalized to all chemoresistant recurrences, there is 
evidence demonstrating that chemoresistant tumor recurrence can occur through this pathway. In 
a study by Saigusa, et al., the levels of stem cell markers CD133, OCT4 and SOX2 were 
evaluated before and after combination radiation and chemotherapy in 33 patients with rectal 
cancer. This study demonstrated that patients with resistant recurrences showed higher levels of 
the stem cell markers and the elevation in stem cell markers were correlated to shorter disease 
free survival (Saigusa et al., 2009). This study further demonstrates the close association with 
resistant phenotypes and stem cells in colon cancer. Similar studies have shown that xenogeneic 
colorectal cancer cells show increased expression of ALDH1A1 which conferred the ability to 
detoxify cyclophosphamide, a classical chemotherapeutic agent (Dylla et al., 2008).  In 
agreement with these findings, Yang, et al. developed a substrain of the colorectal cancer cell 
line HCT 116 which was resistant to oxaliplatin. It was observed that the oxaliplatin resistant 
strain was additionally resistant to treatment with paclitaxel implying a mode of resistance that 
was not mechanism specific to oxaliplatin. This cell line also showed a greater portion of G0/G1 
arrest implying quiescence, higher spheroid formation capacity, higher expression of ABCG2 
and enriched for stem cell markers (Yang et al., 2013). These studies demonstrate that the cells 
capable of surviving and following chemotherapy may have strong stem cell-like characteristics 
such as slowed cell cycle progression, increased stem cell marker expression and increased 
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Figure 3: Diagram representing the hierarchical model of cancer in response to 
chemotherapy. Classical chemotherapies target rapidly proliferating progeny of 
cancer stem cells resulting in rapid shrinkage of the tumor leaving only CSCs as 
remaining malignant cells. Tumors relapse once CSCs being to regenerate 
progeny. Stem cell targeted therapies would theoretically inhibit pathways 
required for stem cell survival resulting in loss of self-renewal capacity in tumors 
leading to spontaneous tumor regression following death of proliferative progeny. 
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expression of ABC transporters. Additionally, in a recent study published by Merlos-Suarez, et 
al, gene signatures were established for physiologic ISCs and transit amplifying cells which were 
then used to show that only cells containing the gene signature of ISCs were the capable of 
generating a recurrent colorectal cancer (Merlos-Suarez et al., 2011). Similar studies validate 
these findings in other tissues such as ovaries, prostate, liver and lung (Bisson and Prowse, 2009; 
Chau et al., 2013; Kawabata et al., 2001; Noda et al., 2009; Yang et al., 2008b). Taken as a 
whole, these studies show that colorectal cancer originates from a population of dysregulated 
stem-like cells that resist initial rounds of chemotherapy and generate a chemoresistant recurrent 
tumor. 
The range of mechanisms that cancer cells employ include suppression of the apoptotic response, 
acquisition of quiescence, upregulation of drug elimination pathways and mutation of the target 
of the chemotherapy. One of the primary mechanisms of chemoresistance in CSCs is 
overexpression of ATP binding cassette (ABC) transporters to attain multidrug resistance. ABC 
transporters are transmembrane transporters that utilize the hydrolysis of ATP to efflux a broad 
range of lipophilic xenobiotics in order to protecting the cell from the activity of many cytotoxic 
agents regardless of their mechanism of action. Similar to normal adult stem cells, CSCs are 
known to overexpress ABC transporters such as phospho-glycoprotein (Pgp), breast cancer 
resistance protein (BCRP) and multidrug resistance protein (MRP). These transporters confer 
CSCs the ability to actively efflux many conventional chemotherapies such as doxorubicin 
(ADM), paclitaxel, 5-fluoro-uracil (5-FU) and many others (Dean et al., 2005).  
The association between multidrug resistance and stem cells was effectively established upon 
discovery of the “side population” (SP) of bone marrow cells (Goodell et al., 1996). A 
diagrammatic representation of the SP assay is shown (Figure 4). It was revealed that following 
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Figure 4: Diagram of SP assay. The pooled population of cells are exposed to a 
cell permeable fluorescent marker (Hoechst 33342) resulting in the majority of 
cells showing high intracellular fluorescence. A minority of cells show low 
intracellular fluorescence presumably through high levels of efflux activity. 
Fluorescence activated cell sorting (FACS) is capable of separating cells of high 
fluorescence versus cells of low fluorescence (SP). The SP fraction from bone 
marrow has shown >1000-fold increase in differentiation and self-renewal 
capacity. 
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treatment with a cell permeable fluorescent dye, namely Hoechst 33342, a diminishingly small 
population (~0.1%) of mouse bone marrow cells maintained low intracellular fluorescence as 
measured by flow cytometry. Interestingly, these SP cells also displayed a significant enrichment 
in the capacity to self-renew and differentiate implying that the SP population was enriched for 
HSCs. By examining Hoechst 33342 efflux rates in cellular vesicles from cell lines known to be 
enriched for Pgp compared to cell lines known to be low in Pgp expression it was shown that the 
kinetics of Hoechst efflux could be significantly modulated by the expression levels of Pgp 
(Shapiro et al., 1997). This established that Hoechst 33342 was a substrate of Pgp and implied a 
possible causative link between SP cells and ABC transporters. Further confirmation that Pgp 
expression is a prominent feature of HSCs came, when Scharenberg, et al. demonstrated that the 
HSCs showed high levels of Pgp mRNA initially, but upon lineage commitment and 
differentiation, significantly downregulated transcript levels of Pgp (Scharenberg et al., 2002). 
SP cells have also been demonstrated in the gastrointestinal tract. Upon examination of 16 cell 
lines, fifteen showed the presence of the SP which also showed characteristics of stem cells 
(Haraguchi et al., 2006). The presence of SP cells and their link to stem cell characteristics have 
also been demonstrated in breast, ovarian and hepatocellular carcinoma as well (Chiba et al., 
2006; Christgen et al., 2007; Szotek et al., 2006).  
In conjunction with Pgp, BCRP and MRP are two additional ABC transporters important to the 
efflux based multidrug resistance phenotype in cancer. Overexpression of BCRP confers 
multidrug resistance with some overlap of multidrug resistance conferred by Pgp (Litman et al., 
2000). Further studies demonstrated BCRP as a potential characteristic of stem cells when it was 
shown to be upregulated in stem cells of various tissues and downregulated upon terminal 
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differentiation (Zhou et al., 2001). Additionally, it was observed that following overexpression of 
BCRP, cells were more prone to retain a stem like state.  
The MRP family of proteins contains MRP1 through 6 with MRP1 and MRP2 having shown 
significant roles in multidrug resistance of cancer. MRP1 is fairly ubiquitously expressed and 
MRP2 is localized more toward the liver, kidney and gut (Borst et al., 1999). Additionally, the 
MRP family of transporters have been shown to generate chemoresistance to several 
chemotherapeutic agents including ADM and paclitaxel (Szakacs et al., 2006). Important to note 
is that these transporters share some overlap in the xenobiotics they are capable of effluxing, 
however their kinetics differ granting cells varying cross resistance depending upon which panel 
of transporters it has upregulated (Litman et al., 2000; Szakacs et al., 2006). 
These studies demonstrate that CSCs often acquire the capacity to efflux xenobiotics through the 
upregulation of a subset of ABC transporters such as Pgp, BCRP and MRP which can contribute 
to multidrug resistance. Additionally, these transporters are responsible for the formation of the 
SP fraction that also show significant enrichment for stem cell characteristics. Important to note 
however is that although many attempts have been made to inhibit efflux transporters to 
reestablish chemosensitivity, none have yet to be successful and progress is still slow-moving 
(Szakacs et al., 2006). Directly targeting the mechanisms that establish the CSC may be the 
viable alternative rather than attempting to subvert effects secondary to cancer “stemness.” 
 
Regulation of ISCs and CSCs by the Wnt/β-catenin signaling pathway 
Due to the relative importance of CSCs, it is important to understand the cellular signaling 
pathways that can regulate the ISC and CSC compartments and factors that can modulate the 
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activity of these signaling pathways. One such pathway governing the maintenance of ISCs is the 
Wnt/β-catenin signaling pathway. A schematic representation of the canonical Wnt/β-catenin 
signaling pathway is shown for reference (Figure 5). Normally β-catenin exists in three primary 
pools. In most intestinal epithelial cells β-catenin is primarily observed at the membrane and acts 
as an anchoring protein linking the actin cytoskeleton to the extracellular adhesion molecule E- 
cadherin (Ozawa et al., 1990). Additionally, there is a minimal and transient pool of β-catenin in 
the cell cytoplasm. This pool of β-catenin experiences high turnover due to rapid degradation by 
a destruction complex composed of APC, Axin, and the two serine/threonine kinases glycogen 
synthase kinase 3β (GSK3β) and casein kinase 1 (CK1). This complex binds cytoplasmic β-
catenin at which point CK1 primes β-catenin through phosphorylation of β-catenin at Ser45. This 
allows GSK3β to phosphorylate β-catenin at Ser33, Ser37 and Thr41 (Liu et al., 2002). 
Phosphorylation of β-catenin at these sites leads to binding of β-catenin to β transducing repeat 
containing protein (βTrCP) leading to polyubiquitinilation of β-catenin followed by proteasomal 
degradation.  
Under specific exogenous conditions β-catenin degradation is inhibited. For example, the 
canonical Wnt/β-catenin involves the binding of the extracellular Wnt ligand to the 
transmembrane receptors low density lipoprotein related protein (LRP) 5/6 and Frizzled. 
Following ligand binding, the complex of LRP5/6 and Frizzled inhibit the destruction complex 
through a poorly understood mechanism. One prevailing theory regarding destruction complex 
inhibition is that Wnt ligand binding of LRP5/6 and Frizzled results in sequestration of the 
members of the destruction complex at the cell membrane limiting access to the cytoplasmic 
pool of β-catenin. It was shown that administration of Wnt ligand results in phosphorylation of 
the LRP5/6 receptor in a GSK3β and CK1 dependent fashion and that this phosphorylation is 
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Figure 5: Schematic representation of the Wnt/β-catenin signaling pathway. In 
the absence of exogenous signal β-catenin exists at the membrane associated with 
E-cadherin. The cytoplasmic pool of β-catenin is rapidly degraded by association 
with the destruction complex. β-catenin is initially phosphorylated by CK1 then 
GSK3β tagging it for polyubiquitinylation by β-TrCP. It is then degraded by the 
proteasome. In the presence of Wnt signal, Frizzled and LRP5/6 bind the Wnt 
ligand inducing phosphorylation of LRP and recruitment of Disheveled. 
Disheveled inhibits the destruction complex resulting in accumulation of β-
catenin in the cytoplasm. Cytoplasmic β-catenin then translocates to the nucleus, 
displacing transcriptional repressors such as Groucho and associates with 
TCF/LEF. β-catenin association with TCF/LEF drives transcription of a number 
of β-catenin target genes such as COX-2, IL-8, Cyclin D1 and c-MYC. 
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required for association of LRP5/6 with Axin (Zeng et al., 2005). Phosphorylation of LRP5/6 
results in recruitment of Disheveled to the plasma membrane where it associates with Frizzled 
and sequesters Axin to the cell membrane (Bilic et al., 2007; Yamamoto et al., 2006).  
Inhibition of the destruction complex leads to accumulation of β-catenin in the cytoplasm 
allowing β-catenin to translocate to the nucleus. In the absence of nuclear β-catenin, 
transcriptional repressors such as Groucho bind transcription factor/lymphoid enhancer binding 
factor (TCF/LEF) (Cavallo et al., 1998). Upon translocation to the nucleus β-catenin displaces 
transcriptional repressors such as Groucho and histone de-acetylase (HDAC) and associates with 
TCF/LEF and initiates transcriptional changes within the cell. For a more comprehensive review 
of the Wnt/β-catenin signaling pathway as well as interplay between β-catenin signaling and 
other stem cell signaling pathway such as Notch, the reader is referred to the following sources 
(Fodde and Brabletz, 2007; Nakamura et al., 2007; Reya and Clevers, 2005; van der Flier and 
Clevers, 2009). 
Importantly, β-catenin associated TCF/LEF transcriptional activity has been shown to be critical 
for maintenance of ISCs. In mice lacking Tcf-4, it was noted that intestinal endoderm developed 
normally into epithelium, however, the proliferative compartments within the crypts were absent 
and only terminally differentiated cells remained of the crypt epithelium, implying that the Tcf-4 
transcriptional program is critical to maintaining epithelial stem cells (Korinek et al., 1998). 
Additionally, important mediators of cell cycle and proliferation such as c-MYC and cyclin-D1 
are Wnt target genes implicating the Wnt/β-catenin transcriptional program as being critical for 
promoting expansion of the transit amplifying compartment (He et al., 1998; Tetsu and 
McCormick, 1999).  
29
 
It is important to note that canonical Wnt/β-catenin signaling is a major factor regulating stem 
cell homeostasis in other tissues. For example, HSCs show activity of a TCF/LEF luciferase 
reporter called TOPFlash, and overexpression of active β-catenin can expand the pool of HSCs. 
Additionally, inhibition of Wnt in HSCs using a decoy receptor or inhibition of β-catenin by 
overexpressing Axin results in a diminishing of the HSC pool implying that Wnt/β-catenin 
signaling is important for hematopoiesis at the level of the HSC (Reya et al., 2003).  
If the β-catenin signaling cascade is a major regulator of the intestinal crypt stem cell 
compartment and ISC homeostasis, it would stand to reason that an unregulated overactivation of 
β-catenin transcriptional activity could result in malignant transformation. Indeed, this is the case 
in colon cancer as well as several other neoplasias. One of the major pieces of evidence linking 
the β-catenin signaling cascade to colon cancer tumorigenesis was the discovery that the majority 
of colorectal cancers (estimated to be >80%) contained a homozygous loss of function mutation 
in the APC gene (Fearon and Vogelstein, 1990). Subsequently, it was identified that a 
heterozygous mutation in the APC gene is the hereditary factor contributing to Familial 
Adenomatous Polyposis (FAP), one of two currently known genetic syndromes for colorectal 
cancer implying that loss of functional APC is a major contributing factor to not only sporadic 
but also hereditary colon cancers (Groden et al., 1991). As loss of functional APC is the 
initiating and rate limiting step of oncogenic transformation, it is thought that LOH in FAP 
patients is responsible for generation of multiple colonic adenomas (Kinzler and Vogelstein, 
1997). Further evidence for the role of APC in intestinal tumorigenesis came from mouse studies 
using random mutagenesis to generate a mouse with multiple intestinal neoplasia (MIN) where 
the genetic lesion was found to be in the Apc gene (Moser et al., 1990). In fact, loss of functional 
APC is such a significant regulating step in tumorigenesis that the predominant genetic mouse 
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models for intestinal cancer utilize lesions of the Apc gene to induce spontaneous intestinal 
neoplasias; one of the most commonly used genetic mouse model for intestinal neoplasia is the 
Apc MIN (ApcMin/-) model (Fodde et al., 1994; Moser et al., 1990).  
While this evidence pointed toward APC as a tumor suppressor which upon loss of function 
causes the initiation of colonic neoplasia, evidence linking APC to the β-catenin transcriptional 
program was still lacking. Further studies demonstrated that tumors with loss of functional APC 
showed increased levels of β-catenin with the nuclear fraction of β-catenin associated with 
transcriptionally active TCF/LEF (Korinek et al., 1997). Additionally, reintroduction of 
functional APC transiently into APC deficient colorectal cancer cells showed a significant 
abrogation of nuclear β-catenin and loss of β-catenin transcriptional activity (Korinek et al., 
1997; Munemitsu et al., 1995). Evidence further linking loss of β-catenin regulation as the 
initiating step of colonic tumorigenesis was that many of the tumors with intact APC showed 
mutations of the phosphorylation sites of β-catenin itself  resulting in the inability of CK1 and 
subsequently GSK3β to phosphorylate β-catenin (Morin et al., 1997; Polakis, 2007). Taken 
together, this evidence points to the primary initiating factor of colonic tumorigenesis being the 
overstabilization of β-catenin, either through loss of APC or the inability of the destruction 
complex to target β-catenin itself. Subsequently TCF/LEF transcriptional activity is upregulated 
in response to overstabilization of β-catenin leading to a transcriptional state within the cell that 
generates hyperplasia and adenoma formation.  
Another point to note is that although β-catenin signaling is not specifically established as the 
rate limiting step of oncogenesis, stabilized β-catenin is also a hallmark of several cancers such 
as breast cancer, ovarian cancer, neuroblastoma and hepatocellular carcinoma (Chau et al., 2013; 
Flahaut et al., 2009; Noda et al., 2009; Woodward et al., 2005). For example, it is estimated that 
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over half of breast cancers contain increased levels of β-catenin with increased levels of β-
catenin being associated with a poor prognosis (Woodward et al., 2005). 
While much of the evidence presented thus far implicates β-catenin as the driving force initiating 
adenoma formation, there is also evidence that points to β-catenin dysregulation contributing to 
the progression and increased aggressiveness of colon cancers. The overactivation of β-catenin 
transcription results in numerous changes to cellular biology that can result in a more aggressive 
neoplasia. For example, inactivation of APC or activation of β-catenin drives intestinal 
hyperplasia (Reya and Clevers, 2005). This is thought to be due in part to two major 
transcriptional targets of β-catenin, namely c-MYC and cyclin-D1 both of which are potent 
stimulators of cell cycle progression (He et al., 1998; Tetsu and McCormick, 1999). 
Additionally,  using a dominant negative TCF4 in colorectal cancer cell lines and examination of 
the global transcriptional changes through microarray analysis, it was revealed that the APC -/- 
transcriptional changes closely mirror the transcriptional programs observed at the crypt base 
where the crypt stem cells and progenitors are located (van de Wetering et al., 2002). This 
heavily suggests that the overactivation of β-catenin is the causative factor driving stem cell or 
progenitor cell expansion. An additional transcriptional change seen in overactivation of β-
catenin is an increase in levels of survivin. Survivin expression is found to be increased at the 
crypt base compared to higher along the crypt axis and reconstitution of wild type APC in colon 
cancer cells results in decreased survivin expression (Zhang et al., 2001). Increased survivin 
expression serves to inhibit caspase activity and protect the cell from apoptotic pathways (Tamm 
et al., 1998). This is theorized to be a potential mechanism behind the apoptosis observed in 
colon cancer cells with reconstituted wild type APC and also implicates overactivation of β-
catenin as a CSC inducer as CSCs tend to suppress apoptotic pathways. 
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Overactivation of the Wnt/β-catenin pathway has also been implicated in the acquisition of 
chemoresistance. A recent study has shown that human hepatocellular carcinomas refractory to 
5-fluorouracil (5-FU) treatment show higher levels of β-catenin activity and that if cells are 
treated with 6-bromoindirubin-3’-oxime (BIO), an inhibitor of GSK3β, to upregulate β-catenin 
activity, cells show increased multidrug resistance (Noda et al., 2009). In agreement with this, it 
was also demonstrated that ADM resistant neuroblastomas had upregulated MRP1 which 
correlated with increased nuclear β-catenin staining. Upon inhibition of β-catenin, MRP1 levels 
decreased with significant sensitization to ADM (Flahaut et al., 2009). Additional studies have 
also correlated resistance to paclitaxel and cisplatin in ovarian cancers with activation of Wnt/β-
catenin signaling as well as upregulation of BCRP (Chau et al., 2013). These studies reveal that 
β-catenin activity can contribute to the multidrug resistance phenotype associated with many 
aggressive neoplasms as discussed earlier. 
Important to note also is that loss of functional APC and increased nuclear β-catenin does not 
solely result in transcriptional changes but also induces changes such as cell migration and 
intercellular adhesion. In cancer conditions, the association of β-catenin with E-cadherin remains 
intertwined and changes in the membrane associated β-catenin pool is mirrored by similar 
changes in E-cadherin (van der Wurff et al., 1997). Additionally, it has been noted that nuclear β-
catenin is more prominently expressed at the migrating front of tumors compared to central 
regions of tumors (Brabletz et al., 1998). This is heavily suggestive that E-cadherin and β-catenin 
together have major effects on maintaining cell polarity and adhesion. 
Additionally, Brabletz, et al. noted that nuclear β-catenin levels progressively increase as cancers 
progress from low grade adenomas to high grade adenomas demonstrating a dose dependence of 
β-catenin activity in colon cancer (Brabletz et al., 2000). To further elucidate this phenomenon, 
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studies were conducted to observe the dose dependent effects of β-catenin. By using a series of 
hypomorphic mutants of APC, it was observed that these different mutations in APC generated 
different degrees of β-catenin overactivation, and more importantly, the degree of β-catenin 
overactivation correlated with the number of polyps formed within the intestine (Gaspar and 
Fodde, 2004). This finding implies that a dosage dependence of β-catenin activity can confer the 
capacity to undergo different transcriptional programs and may account for the pleiotropic 
effects observed upon loss of APC and subsequent overactivation of β-catenin. 
As tumors at the invasive front show higher levels of nuclear β-catenin it is presumable that they 
should show lower levels of E-cadherin and a more mesenchymal phenotype while also 
maintaining a high proliferative index. However, studies have shown that cells within these 
invasive fronts, while showing an epithelial-to-mesenchymal transition (EMT) with loss of E-
cadherin and higher nuclear β-catenin, actually demonstrate a paradoxical lower rate of 
proliferation (Jung et al., 2001). In fact, Jung, et al. showed that compared to central regions of 
tumors showing a more differentiated phenotype with lower nuclear β-catenin, the invasive 
fronts generally showed low levels of the proliferative marker Ki-67. It is presumable, that based 
on context and the dose dependence of nuclear β-catenin that these cells experience an 
alternative transcriptional program generating a distinct phenotype. This transcriptional program 
may induce a more quiescent phenotype with more invasive characteristic for some CSCs.  
Most important to note however, is that although the majority of colon cancers display a loss of 
APC function or inability of the destruction complex to target β-catenin, there is still 
heterogeneity of β-catenin signaling within the tumor. This implies that while the loss of the 
canonical mechanism of β-catenin regulation is important there are numerous other factors yet to 
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be discovered that regulate the activity of this pathway to potentially modulate the many 
phenotypic characteristics associated with Wnt/β-catenin signaling. 
 
RBM3 and its physiologic roles 
Recently, several reports have emerged on an RNA binding protein revealing a role in the 
initiation and progression of different solid tumors. Expression of the RNA binding motif 
containing protein 3 (RBM3) has been recently shown to be upregulated in several solid tumors 
to varying degrees with higher expression occurring with more aggressive or higher grade 
tumors. It has also been shown to serve as an oncogene when overexpressed implicating its role 
in tumor initiation. However, the exact mechanism responsible for RBM3 mediated oncogenesis 
and tumor progression is still poorly understood. Here we outline the current knowledge relating 
to RBM3 and its role in cellular physiology and cancer. Furthermore, we go on to describe the 
rationale linking previous studies to the hypothesis of RBM3 being a stem cell regulating factor. 
 
RNA binding proteins known to affect stem cell phenotype 
While the potential for RBM3 regulating stem cell behavior is fairly novel, it should be noted 
that it is not unprecedented that RNA binding proteins can alter stem cell behavior. Previous 
studies have elucidated the potential for Musashi1 (Msi1), Human antigen R (HuR) and Lin28 as 
some examples of RNA binding proteins capable of modulating stem cell behavior through 
various molecular mechanisms. 
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Lin28 could currently be one of the most prominent RNA binding proteins to affect stem cell 
regulation. It was first discovered in C. elegans under regulation of the let-7 miRNA (Ambros 
and Horvitz, 1984). It was subsequently shown that the mouse homolog is also regulated by let-7 
implying a highly conserved mechanism of regulation. Furthermore, it is highly expressed in 
mouse embryonic cell and significantly downregulated following terminal differentiation (Moss 
and Tang, 2003). One of the primary pieces of evidence linking Lin28 to the regulation of stem 
cells was shown in work by Yu, et al. where it was demonstrated that Lin28 is one of four factors 
required to generate induced pluripotent stem cells (iPSCs) from mouse fibroblasts (Yu et al., 
2007). The mechanism of Lin28 mediated stem cell induction was unclear until it was 
demonstrated that  the molecular mechanism governing Lin28 action was based on its ability to 
suppress the maturation of let-7 miRNA (Viswanathan et al., 2008). It was further demonstrated 
that Lin28 could act upon cells to promote oncogenic transformation and aid in progression of 
malignancy (Viswanathan et al., 2009). This implies that in the developmental context, Lin28 is 
required for maintaining “stemness” and is soon downregulated in terminally differentiated 
tissues. It is also upregulated in cancers presumably to maintain self-renewal of CSCs. For a 
more comprehensive review, the reader is referred to the following source (Shyh-Chang and 
Daley, 2013). 
Msi-1 is an RNA binding protein with a well-established mechanism for stem cell regulation. In 
order to discover its roles within the cell, the systematic evolution of ligands by exponential 
enrichment (SELEX) technique was used to determine the Msi-1 consensus binding sequence. 
Based on this information it was demonstrated that Msi-1 could bind the 3’-UTR of m-Numb 
mRNA and inhibit its translation. Additionally, Msi-1 overexpression resulted in suppression of 
m-Numb protein (Imai et al., 2001). As m-Numb is a primary repressor of the Notch signaling 
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cascade, a pathway critical for maintaining stem cells in various tissues, the established 
mechanism of action of Msi-1 is by suppressing the suppressor of Notch signaling. Importantly, 
Msi-1 also has significant effects on cancer as it was demonstrated that upon siRNA mediated 
knockdown of Msi-1 in tumor xenografts, cells underwent growth arrest with reduced tumor 
growth coupled with inhibition of Notch signaling (Sureban et al., 2008a). 
HuR was initially discovered as a ubiquitously expressed RNA binding protein with affinity for 
AU-rich elements (Ma et al., 1996). Depletion of HuR in mice leads to degeneration of rapidly 
renewing tissues such as crypt epithelium and bone marrow (Ghosh et al., 2009). This implies 
that HuR is an important protein for maintaining proliferation of rapidly cycling organs at least at 
the level of the proliferative progeny of the stem cells. Interestingly, HuR has also been shown to 
associate with β-catenin protein (Kim et al., 2012b). The importance of this binding was further 
emphasized following a study showing HuR to be critical for maintaining stem-cell 
characteristics under conditions of hypoxia through binding of β-catenin and client mRNAs 
(D'Uva et al., 2013). HuR localization also appears to play an important role in stem cell function 
as undifferentiated myoblasts show accumulation of HuR within the nucleus but upon 
differentiation, HuR appears to transition to the cytoplasm (van der Giessen and Gallouzi, 2007). 
Importantly, HuR has been shown to be critical in the early progression of colon cancer through 
alteration of COX-2 expression (Young et al., 2009). While it is currently unclear the degree of 
regulation HuR imparts upon stem cells or the mechanism responsible for this regulation, HuR 
remains an important protein of interest in regards to stem cell regulation and cancer 
pathogenesis. 
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RBM3 discovery and regulation 
RBM3 was originally discovered through cDNA selection in yeast artificial chromosomes of the 
Xp11.2 region. The longest open reading frame of RBM3 yields a 157 amino acid long protein 
that has a putative RNA recognition motif. Due to homology to an RNA binding protein in maize 
it is presumed that RBM3 may serve a fundamental role in cellular biology that is carried over 
from plants to animals (Derry et al., 1995). The first factor discovered to modulate RBM3 
expression was hypothermia. It was shown that while the cell lines that were examined 
maintained basal levels of RBM3 expression, exposure to mild cold shock (specifically 24 hours 
at 32°C) was capable of significantly upregulating RBM3 mRNA levels. Interestingly, transcript 
levels were also increased upon exposure to translation inhibition agents such as puromycin and 
cycloheximide (Danno et al., 1997).  In accordance with these findings, it was shown that Rbm3 
expression was significantly increased in the Sertoli cells of mouse testes which reside in an 
environment of approximately 32°C. Interestingly, increasing temperature of the testes to 37°C 
resulted in abrogation of RBM3 expression (Danno et al., 2000). 
As many cold shock response proteins serve roles in post-transcriptionally regulating mRNA, it 
was proposed that RBM3 may serve a role in regulating RNA by altering translation, stability or 
splicing of transcripts Cyclooxygenase 2 (COX-2) is a proinflammatory enzyme that is 
responsible for the rate-limiting conversion of arachadonic acid into inflammatory mediators. 
While COX-2 is expressed in low levels under normal conditions, it is induced to high levels 
following exposure to lipopolysaccharide (LPS) (Roshak et al., 1994). One major method of 
regulating COX-2 levels in the cell is with rapid turnover of the mRNA thereby maintaining very 
low levels of COX-2 mRNA (Newton et al., 1997). Upon exogenous stimuli such as exposure to 
LPS, COX-2 mRNA half-life is significantly increased (Barrios-Rodiles et al., 1999). In order to 
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identify potential proteins that could alter COX-2 mRNA stability, the 3’ untranslated region 
(UTR) was conjugated to biotin and incubated with nuclear proteins. The bound protein was then 
isolated, subjected to two dimensional Western analysis and mass spectrometry. Using this 
method, RBM3 was identified as a protein that could bind the Cox-2 3’UTR (Cok et al., 2004). 
Additional studies using actinomycin-D treatment, an inhibitor of de novo mRNA synthesis, 
established that RBM3 overexpression was capable of increasing the half-life of COX-2 mRNA 
(Sureban et al., 2008b). This evidence points strongly toward RBM3 as a potential factor that can 
alter the progression of colon cancer as COX-2 overexpression is thought be an early event in its 
progression. Another major study to elucidate the cellular function of RBM3 came when it was 
revealed that RBM3 is upregulated by hypoxia. Exposure of Z-33 human leukemia cells and 
Hepa-1 mouse hepatoma cells to moderate and severe hypoxia (8% and 1% O2 respectively) 
resulted in significant increases in protein levels of RBM3 (Wellmann et al., 2004). This increase 
was abrogated by the use of actinomycin D implying that hypoxia induced increases in RBM3 
were at the transcriptional level. Interestingly, these cell lines are deficient for specific hypoxia 
inducible factors (HIFs). Z-33 cells are deficient in HIF-1α and Hepa-1 cells are deficient in 
HIF-1β implying that this upregulation of RBM3 was independent of HIF based transcription. 
The first major piece of evidence of RBM3 being associated with stem cells came from a study 
investingating RBM3 levels within HSCs (Baghdoyan et al., 2000). Using a gene trap approach, 
it was shown that RBM3 was specifically upregulated during treatment with granulocyte 
monocyte colony stimulating factor (GM-CSF). Additionally, GM-CSF treatment increased the 
CD34+ HSC pool which showed a selective increase in the RBM3 transcript level (Baghdoyan et 
al., 2000). A second study also confirmed that in a mouse model for spontaneous hemolytic 
anemia, erythropoietic CD34+ stem cells showed increased RBM3 levels (Yang et al., 2008a). 
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This major finding was the first implication that RBM3 may have a significant role in regulating 
the proliferation of stem cells by showing that it is upregulated in proliferating HSCs.  
 
RBM3 and cell survival under stress 
While many studies show how RBM3 is regulated under specific conditions and its expression 
levels in certain disease states, there are few studies showing direct effects of altered RBM3 
expression on the biology of cells. One of the earlier studies of RBM3 function was revealed 
using RBM3 overexpression in neuroblastoma cells. RBM3 overexpression in this context 
showed an increase in total protein synthesis under conditions of either euthermia or 
hypothermia. It was further shown that RBM3 overexpression showed global changes in 
microRNA (miRNA) levels implying that RBM3 can act as a global regulator of protein 
synthesis by modulating miRNA levels (Dresios et al., 2005). Further confirmation of this effect 
was demonstrated recently by showing that RBM3 overexpression does indeed alter miRNA 
levels on a global scale and that RBM3 appears to alter the processing of miRNAs within the 
cytoplasm at the processing step involving Dicer (Pilotte et al., 2011). These studies imply that 
RBM3 could affect cellular biology at a very fundamental and very global scale to induce 
widespread changes following certain stress conditions such as cold shock, hypoxia or serum 
deprivation.  
The first studies to reveal that RBM3 may have some role in cell death and apoptosis came from 
Kita, et al. where apoptosis was induced by conditionally overexpressing the polyglutamine 
repeat responsible for neurodegeneration in Huntingon’s disease. It was revealed that RBM3 was 
upregulated in the early stages of apoptosis, however, exogenous overexpression of RBM3 
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impaired polyglutamine repeat induced cell death in both neural and non-neural cells (Kita et al., 
2002). In agreement with this study, it was also shown that exposure of the marine biotoxin 
dominoic acid induces upregulation of RBM3 in the early stages of apoptosis however this study 
did not specifically address if the upregulation of RBM3 was a part of the cell death process or a 
compensatory cytoprotective factor (Ryan et al., 2005). A recent study addressed this and 
showed that RBM3 is a necessary protein for cell survival. Overexpression of RBM3 in primary 
neurons under conditions of hypothermia showed significant abrogation of apoptosis whereas 
siRNA mediated RBM3 knockdown resulted in increased cell death under hypothermia (Chip et 
al., 2011). This study concluded that the clinical use of hypothermia to preserve brain function 
following injury could be mediated by RBM3. RBM3 overexpression, either exposure to cold 
shock or through vector transfection of an RBM3 overexpressing construct, also showed 
significant protection from apoptosis in C2C12 myoblast cells. Treatment of cells with 
staurosporine or H2O2, both of which normally induce apoptosis, was not as effective in inducing 
apoptosis in cells exposed to cold shock or cells overexpressing RBM3 (Ferry et al., 2011). This 
implied that RBM3 may have a role in inducing cytoprotective effects on cells following 
exposure to the stressor conditions it is upregulated by, namely hypoxia and cold shock. 
Additionally, as RBM3 overexpression attenuated the apoptosis response following 
staurosporine and H2O2 treatment, it may serve as an inhibitor of apoptosis under many 
conditions.  
RBM3 also appears to have effects on regulation of cell cycle progression and proliferation. 
siRNA mediated knockdown of RBM3 in colon cancer cells resulted in cells accumulating at the 
G2/M phase of cell cycle and subsequently undergo apoptosis (Sureban et al., 2008b). A study 
by Wellmann et al. further confirmed that RBM3 serves in this role. These studies revealed 
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several insights into the physiologic roles of RBM3. Primarily, it was observed that RBM3 
mRNA transcript levels closely mirrored proliferation rates in human fibroblasts and HEK293 
embryonic kidney cells. Inhibition of proliferation using serum deprivation or contact inhibition 
showed decreases in RBM3 levels while forced overexpression of RBM3 showed rescue of 
serum deprivation induced growth arrest. Additionally, siRNA-mediated RBM3 knockdown 
showed cells eventually losing proliferative capacity and undergoing cell death (Wellmann et al., 
2010). Additionally, this study further confirmed by IHC that RBM3 was increased in colon and 
prostate adenomas compared to normal, terminally differentiated tissue.  
 
RBM3 expression and cancer 
One of the most prominent studies of the potential role that RBM3 may serve in colon cancer 
showed that RBM3 is capable of inducing oncogenic transformation (Sureban et al., 2008b). 
First, it was demonstrated that if RBM3 was overexpressed in NIH/3T3, non-transformed, 
immortalized mouse fibroblasts, the cells were capable of anchorage independent growth, a 
marker of malignant transformation. This is currently one of the strongest pieces of evidence 
suggesting that RBM3 overexpression can be oncogenic.  Second, this study also was the first to 
reveal that RBM3 mRNA and protein levels are elevated in colon cancer in a stage dependent 
manner compared to normal adjacent tissue. Additionally, IHC of tumor microarrays revealed 
that RBM3 immunoreactivity was increased in breast, pancreatic, lung, ovarian and prostate 
cancers. Finally, it was also revealed that in addition to COX-2 mRNA, interleukin-8 (IL-8) and 
vascular endothelial growth factor (VEGF) mRNA half-lives were increased following RBM3 
overexpression revealing a more mechanistic role for RBM3 in oncogenic transformation and 
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potentially progression. Zeng, et al. demonstrated that using either heat shock or small 
interfering RNAs (siRNAs) to knock down expression of RBM3, prostate cancer cell lines were 
more susceptible to the chemotherapeutic agents cisplatin and ADM (Zeng et al., 2009). This 
further shows that RBM3 may play a role in progression of cancers by mediating an increase in 
the multi-drug resistance phenotype.  
Following the finding that RBM3 is upregulated in colon cancer numerous studies have shown 
RBM3 expression levels in other cancers. In a subsequent study, RBM3 was measured in human 
astrocytoma using real-time RT-PCR, Western blot and IHC. RBM3 transcript levels were 
greater than 5-fold in grade III-IV astrocytomas (by World Health Organization grading criteria) 
and approximately 1.6-fold greater in grade I-II compared to adjacent normal tissue. The RBM3 
positive staining rate by IHC was revealed to be 92.5% in grade IV astrocytomas falling to 
37.5% in normal brain tissues. This data implies that RBM3 may have a role in both astrocytoma 
carcinogenesis as well as progression of astrocytoma (Zhang et al., 2013). In a study of RBM3 in 
prostate cancer, RBM3 levels were examined using IHC on tissue microarrays containing over 
11,000 prostate cancer samples. Higher RBM3 expression was correlated to advanced tumor 
stage, Gleason score and metastasis to lymph nodes. 25.6% of tumors from the microarray 
showed strong staining of RBM3 which was correlated to deletions in PTEN. RBM3 expression 
was also correlated with recurrence. This study demonstrates that RBM3 serves as a strong 
independent prognostic marker of prostate cancers (Grupp et al., 2013). In agreement with this 
data, microarray analysis of human prostate cancer tissues showed that in poorly differentiated 
prostate cancer compared to moderately differentiated tumors or normal tissue, RBM3 transcript 
levels were elevated (Shaikhibrahim et al., 2013). 
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From the evidence presented by these studies, it would appear that RBM3 shares a loose 
correlation with stem cells. Primarily, RBM3 expression is upregulated in the CD34+ HSC 
population following GM-CSF treatment. Second, RBM3 is upregulated by hypoxia and CSCs 
are enriched within hypoxia. Third, CSCs are particularly resistant to apoptosis and 
chemotherapy and RBM3 is implicated in resistance to apoptosis and chemoresistance. 
Additionally, RBM3 overexpression has been shown to be oncogenic and upregulation of the 
stem cell compartment is thought to be an initiating event in oncogenesis. Finally, RBM3 
expression seems to correlate with a poor prognosis in cancer. Importantly, the current evidence 
only implies a correlative link between RBM3 and the CSC. Currently any causative evidence is 
lacking. 
In this study, we provide evidence that exogenous RBM3 overexpression is capable of increasing 
the population of stem cells. Furthermore, this increase in the stem cell population is correlated 
with an increase in chemoresistance further confirming that RBM3 overexpression can result in a 
functional change in cancer cells. These studies also show a novel link between RBM3 and the 
Wnt/β-catenin signaling pathway showing the mechanism driving the RBM3 induced stem cell 
phenotype. Taken together these data show a causative link between RBM3 and the stem cell 
phenotype as well as the stem cell signaling pathway that RBM3 modulates. 
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Chapter II: Overexpression of RBM3 increases stem cell characteristics and 
chemoresistance in colon cancer cells 
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Introduction 
RBM3 expression levels as measured by protein and mRNA levels in solid tumors appear to 
increase as cancers become progressively more aggressive (Grupp et al., 2013; Lleonart, 2010; 
Shaikhibrahim et al., 2013; Sureban et al., 2008b; Zeng et al., 2009; Zhang et al., 2013). 
Additionally, most tumors even at earlier stages appear to have significantly elevated RBM3 
levels compared to normal adjacent tissue. Finally, current evidence for the physiologic functions 
of RBM3 points toward a potential role in regulating stem cell populations (Lleonart, 2010; 
Yang et al., 2008a). Additional studies strongly point toward RBM3 being linked with both the 
initiation and progression of astrocytoma, colon and prostate cancer. Unfortunately, most of the 
current studies only show correlative data linking RBM3 to oncogenesis and tumor progression 
and fail to show any major causative evidence or mechanistic data. Here we demonstrate that 
RBM3 overexpression is capable of inducing a phenotypic change that results in an increase in 
the percentage of cells with stem-like properties. Additionally, we present evidence that RBM3 
overexpression is capable of increasing the chemotherapy resistance phenotype through increase 
of ABC transporter activity. This evidence implies a strong correlative link between RBM3 and 
the initiation and progression of cancer. 
  
Rationale 
In order to discern a potential causative link between RBM3 expression levels and colon cancer 
progression, we exogenously modulate RBM3 expression using a doxycycline (Dox) inducible 
lentiviral RBM3 overexpression construct in both HCT 116 and DLD-1 cells. We presumed that 
because the physiologic functions of RBM3 share a significant amount of overlap with known 
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characteristics of stem cells, then if RBM3 plays a role within the biology of cancer cells, it 
would likely be in the regulation of the stem cell compartment. Also, as a dysregulation in the 
stem cell pool is thought to lead to the initiation of colon cancer, we hypothesize that if RBM3 is 
capable of altering stem cell homeostasis, this could be a potential explanation for its previously 
demonstrated role as an oncogene. Furthermore, as expansion of the CSC fraction correlates with 
increased aggressiveness of colorectal cancer, we also propose that increased RBM3 expression 
in advanced cancers causes an expansion of the CSC population that leads to poor prognosis 
associated with high RBM3 expression. 
 
Stem cell population measurement 
We measure the change in stem cell population using two functional assays for stem cell 
population as well as quantifying expression of the stem cell markers DCLK1, LGR5 and CD44. 
As mentioned previously, studies have demonstrated that isolation of the SP fraction yields a 
population that is highly enriched for self-renewal and differentiation capacity (Goodell et al., 
1996). SP cells have also been shown to be upregulated in many primary tumors and cancer cell 
lines (Chiba et al., 2006; Christgen et al., 2007; Haraguchi et al., 2006; Hirschmann-Jax et al., 
2004; Szotek et al., 2006). This observation implies that alterations in the SP percentages could 
represent alterations in stem cell homeostasis as well as an increase in MDR. Additionally, in the 
context of cancer, SP fractions may be a method to measure and isolate the CSC population. On 
the other hand, global alteration in the intracellular fluorescence profile would indicate global 
changes in ABC transporter expression rather than increased expression in the discrete 
population of SP cells. 
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The second functional method of measuring stem cell characteristics is the spheroid formation 
assay. This assay is an in vitro culture system initially established in the culture of neurospheres 
where these cells were revealed to be highly enriched in stem cell characteristics (Reynolds and 
Weiss, 1996). The spheroid forming cells were shown to be capable of increased differentiation 
into neurons, astrocytes and oligodendrocytes. Additionally, spheroid forming cells were capable 
of sustained iterations of spheroid formation implying self-renewal capacity as well. Essentially, 
the assay relies on exposing the heterogeneous cell population to a combination of anchorage 
independent growth and serum deprivation resulting in an environment where only stem cells 
have the capacity to proliferation and other cells undergo apoptosis. Additionally, spheroid 
assays often take place over the course of seven to ten days allowing cells with self-renewal 
capacity to maintain spheroids. An elegant study by Dontu, et al. showed that cells cultured as 
spheroids have been shown to have significant increases in self-renewal and differentiation 
capacity for mammary epithelial culture establishing mammospheres as a culture method for 
expanding stem cells in vitro (Dontu et al., 2003). Interestingly, this study also revealed that the 
spheroid forming stem cell also resides within the SP fraction providing confirmation that both 
assays enrich for stem cells. Spheroid forming capacity has also been shown to be a valid in vitro 
culture method for expanding stem cells for colonic epithelial cells (Kanwar et al., 2010; Ricci-
Vitiani et al., 2007). Here we use spheroid formation capacity in colonospheres as a method for 
measuring “stemness” within the RBM3 overexpressing colon cancer cell lines. 
Finally, the expression of DCLK1, LGR5 and CD44 has been shown to mark colonic CSCs 
(Barker et al., 2009; Barker et al., 2007; Dalerba et al., 2007; May et al., 2008; Qing-Bin et al., 
2013; Verissimo et al., 2012). We measured changes in the percentage of cells positive for stem 
cell marker expression. As previously discussed, a consensus has yet to be reached on a single 
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reliable stem cell marker for either ISCs or CSCs, so we confirm this data with the two 
mentioned functional assays to provide compelling evidence that RBM3 overexpression 
increases the percentage of stem cells in a given cancer cell population. 
 
Materials and Methods 
Cell culture 
HCT 116 and DLD-1 cell lines were obtained from ATCC and cultured under conditions of 5% 
CO2 in Dulbecco’s Modified Eagle Medium (DMEM) (Corning) containing 10% fetal bovine 
serum (FBS) (Sigma-Aldrich) and 1% antibiotic/antimycotic solution (Corning). Following 
transduction of tGFP or tRBM3 plasmids, cells were cultured as mentioned above with 
additional 1 mg/mL G 418 (Santa Cruz Biotechnology) and 1µg/mL puromycin (Life 
Technologies). 
 
Lentivirus propagation and infection 
The Tet-On Advanced tetracycline inducible empty vector system (ClonTech Laboratories, Inc.) 
was used to generate an inducible RBM3 overexpressing system. Tetracycline inducible RBM3 
plasmids were generated using the In-Fusion cloning system (ClonTech Laboratories, Inc.) to 
insert the human RBM3 gene into the multiple cloning site of the pLVX-Tight-Puro vector 
according to manufacturer recommendations. Using this approach, three plasmids were 
generated: pLVX-tRBM3, pLVX-tGFP and pLVX-tGFP-RBM3 where pLVX-tRBM3 is the Dox 
inducible human RBM3, pLVX-tGFP is Dox inducible enhanced green fluorescent protein 
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(eGFP) and pLVX-tGFP-RBM3 is a Dox inducible eGFP/RBM3 fusion protein. Lenti-X cells 
were obtained from Dr. Roy Jensen and were used to generate virus. Lenti-X cells were 
transfected with 7.5 µg of each of the pGIPZ packaging plasmids obtained from Dr. Roy Jensen 
as well as 24 µg of the cargo vector (either pLVX-TetOn, pLVX-tRBM3, pLVX-tGFP, or 
pLVX-tGFP-RBM3) using Lipofectamine 2000 (Life Technologies). Viral supernatant was 
collected at 48, 72 and 96 hours following lipofectamine transfection, pooled, clarified through a 
0.45 µm syringe filter and concentrated using the Lenti-X concentrator (ClonTech Laboratories, 
Inc.). Virus was tittered through limiting dilution (10-6 dilution of 10 µL of concentrated virus) 
and colony formation against appropriate selection (1 mg/mL of G 418 for pLVX-TetOn virus or 
1 µg/mL of puromycin for pLVX-tRBM3, pLVX-tGFP or pLVX-tGFP-RBM3 virus). Parental 
control cells were used to ensure no colony formation occurred in untransduced cells.  
Following tittering, HCT 116 and DLD-1 cells were co-transduced in suspension with 4 µg/mL 
polybrene (Sigma Aldrich) using a mean of infection (MOI) of 5 for pLVX-tRBM3, pLVX-tGFP 
or pLVX-tGFP-RBM3 and an MOI of 10 for the pLVX-TetOn. 24 hours following transduction, 
fresh media was added and following 48 hours of transduction dual selection media was added. 
Parental cells were cultured alongside transduced cells for 1 week under similar selection 
antibiotics to ensure that no untransduced cells survived following the 1 week of selection under 
gross inspection by microscopy.  
Following 1 week of selection, cells were evaluated for GFP or RBM3 overexpression by real 
time RT-PCR and western blot using both a dose dependence and time dependence of Dox 
treatment. 
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Western blotting 
Western blot were performed using poly-acrylamide gel electrophoresis within a Miniprotean 
Tetracell apparatus (BioRad) followed by blotting onto 0.45 µm pore size Immobilon polyvinyl 
difluoride membrane (Millipore) using a mini Transblot module (BioRad). Antibodies for RBM3 
were obtained from AbCam (AbCam) or custom generated through Fisher (Thermo Fisher 
Scientific). Antibodies for β-catenin and phospho-β-catenin were obtained from Cell Signaling 
(Cell Signaling Technology) or BD Biosciences (BD Biosciences). Antibodies for GSK3β and 
phosphor-GSK3β were obtained from Cell Signaling (Cell Signaling Technology). 
 
Real time RT-PCR 
Total cellular RNA was isolated using TRIzol reagent followed by reverse transcription using 
SuperScript II in the presence of random hexonucleotide primers (Life Technologies). cDNA 
was then analyzed by real-time RT-PCR using Jumpstart Taq polymerase (Sigma Aldrich) and 
SYBR Green nucleic acid stain (Life Technologies). Threshold crossing values for each gene 
were normalized to glyceraldehyde phosphate dehydrogenase (GAPDH) gene expression. 
mRNA expression was then normalized to fold change relative to uninduced controls. Primers 
used in this study are as follows: 
RBM3: 5’-TGGGAGGGCTCAACTTTAAC-3’ / 5’-ATGCTCTGGGTTGGTGAAG-3’ 
GAPDH: 5’-CAGCCTCAAGATCATCAGCA-3’ / 5’-GTCTTCTGGGTGGCAGTGAT-3’ 
Pgp: 5’-TGCCTTCATCGAGTCACTGC-3' / 5’-TGACGTGGCTTCATCCAAAA-3' 
MRP2: 5’-TGTGACCACAGATACCAGGA-3' / 5’-AAATATTTTGCCTGGGAACC-3' 
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IL-8: 5’-ATGACTTCCAAGCTGGCCGTGGCT-3’ / 5’-
TCTCAGCCCTCTTCAAAAACTTCTC-3’ 
 
SP assay 
SP assay was performed as previously described with minor modifications (Mathew et al., 
2009). In brief, cells were plated at 100,000 cells/mL into 6 well plates with relevant treatments. 
Following 72 hours of treatment cells were trypsinized and resuspended at 1 million cells/mL in 
DMEM and pre-warmed for 15 minutes at 37°C. Cells were then given 50 µM verapamil (Sigma 
Aldrich), as a pan efflux inhibitor, or vehicle for 30 minutes. Cells were then incubated with 10 
µM Vybrant DyeCycle Violet (DCV) (Life Technologies) for 90 minutes at 37°C. Cells were 
then resuspended in ice cold SP buffer containing 2% FBS, 2 mM HEPES, 1 µg/mL 7-amino 
actinomycin D (7AAD) (Life Technologies) in Hank’s balanced salt solution and analyzed on a 
BD LSR II for SP. DCV was excited using a violet diode laser (408 nm) and emission was 
measured with a 450/50 nm bandpass filter (DCV Blue) and 630 nm longpass, 660/40 nm 
bandpass filter (DCV Red). Viability gating was established with 7AAD with excitation at 552 
nm and emission monitored with a 630 nm longpass, 660/40 nm bandpass filter. Cells were 
initially gated for appropriate size using the side scatter (SSC) and forward scatter (FSC). Cells 
were then gated for viability using 7-AAD uptake to eliminate non-viable cells. Finally, the 
location of the SP gate was established using the verapamil treated sample. 
 
Proliferation assay 
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Cells were induced with Dox for 72 hours. Following induction of RBM3 or GFP vector control, 
cells were plated at 50,000 cells per mL into 96 well plates and allowed to adhere overnight 
followed by treatment with paclitaxel or ADM at varying concentrations. Following 48 hours of 
treatment, cells were assayed for proliferation using the hexoseaminidase assay as previously 
described (Subramaniam et al., 2008). Briefly, cell culture medium was removed followed by 
addition of 75 µL hexoseaminidase substrate buffer (7.5 mM sodium citrate, pH 5.0, 3.75 mM 4-
nitrophenyl-N-acetyl-β-D-glucosaminide, 0.25% Triton) per well and incubation at 37°C for 30 
minutes. The reaction was quenched using 112.5 µL of hexoseaminidase developer solution (50 
mM glycine, 5 mM EDTA, pH 10.4) and absorbance at 405 nm was read on a plate reader. 
Percentage proliferation was calculated as absorbance relative to untreated control and curves for 
inhibitory response were fit using GraphPad Prism software (GraphPad). 
 
ADM uptake and efflux assay 
Cells were plated at high concentration (350,000 cells/mL) for uptake assays into 6 well plates. 
Cells were induced with indicated concentrations of Dox for 72 hours. Cells were then treated 
with indicated concentrations of ADM (ADM) for 30 minutes followed aspiration of ADM 
containing media and addition of ice cold stop solution (200 mM KCl, 2 mM HEPES). Samples 
were washed additionally with stop solution to remove residual extracellular or bound ADM. 
Cells were then lysed with MDR lysis buffer (0.1% Triton-X in 0.3N sodium hydroxide) and 
fluorescence was read on a BioTEK plate reader. Lysates were then assayed for protein 
concentration using Bradford protein assay kit (BioRad) according to manufacturer 
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recommendations. Fluorescent measurements were normalized to protein content to establish 
normalized ADM uptake. 
For efflux assays, cells were plated and induced similar to uptake assays. Following induction, 
cells were treated with 375 µM ADM for 2 hours, then washed with PBS twice and allowed to 
efflux into fresh PBS for varying time points. PBS fluorescence was measured and compared to 
standard curve of ADM fluorescence to establish ADM content effluxed. Cells were then lysed 
with MDR lysis buffer to calculate total protein content per well. Efflux capacity was calculated 
as total ADM effluxed per microgram of total protein. 
 
Spheroid formation assay 
Cells were appropriately treated in 2D culture, trypsinized followed by a wash in phosphate 
buffered saline (PBS) to remove residual serum. Cells were then resuspended in spheroid media 
containing 1x B27 supplement, 20 ng/mL basic recombinant fibroblast growth factor (bFGF) and 
20 ng/mL recombinant epidermal growth factor (EGF) (Life Technologies) in DMEM. Cells 
were passed through a 35 µm sieve, counted and plated onto ultra-low attachment surface plates 
(Corning). Spheroid formation was allowed to proceed for 10-14 days followed by spheroid 
quantification and analysis using a Celigo Cyntellect embryoid body counter. 
 
Stem cell marker flow cytometry 
Cells were treated with Dox to induce expression of GFP or RBM3 for 72 hours. Cells were then 
trypsinized then resuspended at 1x106 cells. For DCLK1 and LGR5, cells were stained with 
54
 
Alexafluor 647 (AF647) conjugated LGR5 antibody (BD Biosciences) or PE conjugated DCLK1 
antibody (AbCam) according to manufacturer recommendations. PE conjugation was performed 
using the Zenon PE labelling kit (Life Technologies) according to manufacturer 
recommendations. For the CD44/CD24 experiment, cells were stained using allophycocyanin 
(APCF) conjugated CD44 antibody and phycoerythrin (PE) conjugated CD24 antibody 
according to manufacturer recommendations with the exception of using half the recommended 
concentration of APCF-CD44 antibody (BD Biosciences). Compensation was performed using 
standardized fluorescent beads. 
 
Results 
We first developed HCT 116 and DLD-1 cell lines with stable Dox inducible RBM3, GFP and 
GFP-RBM3 (tRBM3, tGFP, tGFP-RBM3, respectively) expression. We initiated these studies by 
quantifying the time and dose dependence of Dox in these cells. There was a dose-dependent 
increase in RBM3 mRNA expression with maximal induction seen at a concentration of 500 
ng/mL Dox (Figure 1). Importantly, even in the absence of Dox, HCT 116 tRBM3 cells still 
displayed 2.6-fold induction of RBM3 mRNA levels compared to vector control implying that 
the Dox responsive promoter still generates slight overexpression inherently (Figure 2). 
Additionally, time dependence was investigated following treatment with 500 ng/mL Dox which 
reavealed that RBM3 mRNA levels reached maximal induction within 24 hours (Figure 3). We 
next quantified the induction in protein levels in both DLD-1 and HCT 116 tGFP and tRBM3 
cells to validate that the Dox responsive dose and time dependence of mRNA induction 
correlated with protein expression. tGFP and tRBM3 protein expression mirrored mRNA levels 
with the exception of maximal induction of protein only appearing at 48 hours compared to 24 
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Figure 1: HCT 116-tRBM3 cells upregulate RBM3 mRNA in a Dox dose 
responsive fashion. Real time RT-PCR analysis of RBM3 mRNA following 72 
hour induction with indicated concentrations of Dox. mRNA fold change is 
normalized to uninduced control. Graphs show mean fold change with standard 
error of mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 2: HCT 116-tRBM3 cells show minor increase in RBM3 expression in 
the absence of Dox induction. Real time RT-PCR analysis of RBM3 mRNA 
following 72 hour induction with indicated concentrations of Dox. mRNA fold 
change is normalized to uninduced control in HCT 116-tGFP cells. Graphs show 
mean fold change with SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-
test). 
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Figure 3: HCT 116-tRBM3 cells show upregulation of RBM3 mRNA within 24 
hours. Real time RT-PCR analysis of RBM3 mRNA following 500 ng/mL Dox 
treatment for the specified amount of time. mRNA fold change is normalized to 0 
hour control. Graphs show mean fold change with SEM. *P < 0.05, **P < 0.01, 
***P < 0.001 (Student’s t-test). 
61
 
hours for mRNA (Figure 4). This lag is primarily attributed to the need to translate the high 
quantities of mRNA. DLD-1 and HCT 116 tGFP cells were also validated to have Dox induction 
of GFP (Figure 4). To validate that Dox induction generates functionally active RBM3 in HCT 
116 tRBM3, we also validated that RBM3 expression generated an increase in IL-8 expression as 
previously published (Baghdoyan et al., 2000; Sureban et al., 2008b) (Figure 5). Additionally, to 
further characterize dose dependence of Dox based induction we used fluorimetry to quantify 
overall GFP fluorescence following 48 hour treatment with serial dilutions of Dox. In both HCT 
116 tGFP and tGFP-RBM3 cells we observed reliable, robust expression of GFP fluorescence 
(Figure 7). Finally using HCT 116 tGFP and HCT 116 tRBM3 cells we quantified localization of 
free GFP and the GFP-RBM3 fusion protein to validate that RBM3 localization was similar as 
that described in previous studies (Jogi et al., 2009). As expected, GFP expression was diffuse 
across the cell while GFP-RBM3 localization was primarily in the nucleus (Figure 7). 
Interestingly, we observed that GFP-RBM3 was expressed difflusely across the nucleus but 
showed focal localization in nucleolar regions which contrasts with previous reports stating that 
RBM3 localization is nuclear with exclusion from nucleolar regions (Figure 7).  
To measure changes in the stem cell population, we first determined whether there was a change 
in SP percentages following RBM3 induction. SP population was originally described as a 
population of cells with the capacity to efflux Hoechst 33342 (Goodell et al., 1996). However, 
due to limitations with Hoescht 33342 requiring ultraviolet excitation, we opted to use DCV 
which can be excited using a lower energy available laser. The use of DCV in isolating the SP 
fraction has been previously described (Mathew et al., 2009). For these experiments we used an 
induction of 500 ng/mL of Dox for 72 hours. We used the pan-efflux inhibitor Verapamil to 
validate the location of the SP in both DLD-1 and HCT 116 cells (Figure 8). In DLD-1-tRBM3 
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Figure 4: HCT116-tRBM3 and DLD-1-tRBM3 cells show upregulation of 
RBM3 protein in a time and dose dependent fashion. Western blot analysis of 
RBM3 or GFP overexpression in DLD-1 and HCT 116 tGFP or tRBM3 cells 
with indicated concentrations of and times of Dox treatment demonstrating the 
reliability of Dox induction in these cells.  
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Figure 5: RBM3 overexpression generates functional RBM3 protein that can 
induce increased  IL-8 expression. Real time RT-PCR analysis of IL-8 mRNA 
following 72 hours of  Dox treatment with indicated concentrations. mRNA fold 
change is normalized to uninduced HCT 116-tGFP control. Graphs show mean 
fold change with SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 6: Induction characteristics of HCT 116-tGFP and HCT 116-tGFP-
RBM3. Mean fluorescence intensity of GFP in HCT 116-tGFP and HCT 116-
tGFP-RBM3 cells following 48 hours induction with indicated concentrations of 
Dox demonstrating appropriate induction characteristics of Dox treatment. Graph 
represents fluorescence intensity with error bars representing SEM. 
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Figure 7: GFP-RBM3 is primarily localized within the nucleus with focal 
expression within the nucleolus. Fluorescence microscopy of HCT 116-tGFP and 
HCT 116-tGFP-RBM3 cells induced for 72 hours with 500 ng/mL Dox. Cell 
nuclei are stained with DAPI. Free GFP is observed to be diffuse across both 
cytoplasm and nucleus while GFP-RBM3 localizes primarily to nuclei with foci 
within nucleolar regions. 
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Figure 8: DLD-1-tRBM3 cells show increases in SP percentage following Dox 
induction of RBM3. Flow cytometry dot plots of DCV fluorescence in DLD-1-
tRBM3 cells following 72 hours of induction with indicated concentration of 
Dox. Verapamil treatment was used as a pan efflux inhibitor to localize the SP. 
Percentages represent fraction of whole, single and viable cells within the side 
population region. Error bars represent SEM. P values shown are obtained with 
Student’s t-test. 
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cells we observed a fairly high basal SP fraction by comparing verapamil treatment to untreated 
cells. Induction of RBM3 in these cells showed a robust increase in SP percentages (Figure 8). 
HCT 116 cells while showing nearly no basal SP fraction compared to verapamil treated control 
showed a significant induction of SP percentage following RBM3 induction (Figure 9). SP cells 
have the increased capacity to efflux chemotherapeutic agents. In confirmation of this we treated 
HCT 116 tRBM3 with various concentrations of ADM for 30 minutes and measured intracellular 
ADM fluorescence relative to total protein content to measure uptake of ADM. This revealed 
slightly lower ADM uptake in RBM3 induced HCT 116 tRBM3 cells compared to control at 75 
µM ADM (Figure 10). Next, we treated cells with 325 µM ADM for 2 hours and allowed the 
cells to efflux ADM into fresh PBS for varying times. Here we noted that cells overexpressing 
RBM3 were capable of increased ADM efflux over the measured course (Figure 11). 
Interestingly, if we measure intracellular ADM fluorescence by flow cytometry we observe that 
RBM3 overexpressing cells show a distinct population of cells with low intracellular ADM while 
the overall histogram of the ADM positive cells remains largely unchanged (Figure 12). These 
data further implies that a subset of cells is capable of increased efflux, rather than a global shift 
in the efflux capacity of all cells within the heterogeneous cell pool. Finally, we measured 
changes in mRNA levels of the ABC transporters Pgp and MRP2 in HCT 116-tRBM3 cells, and 
we observe that following RBM3 induction there is a time dependent increase in Pgp and MRP2 
(Figure 13). This observation confirms the increase in SP and efflux capacity due to an increase 
in Pgp and MRP2 expression. We next postulated that with a higher SP, RBM3 expression 
should also confer increased resistance to chemotherapies that are substrates of efflux 
mechanisms. To test this hypothesis, we measured cell proliferation following treatment with 
paclitaxel and ADM, both of which are substrates for ABC transporters (Szakacs et al., 2006). 
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Figure 9: HCT 116-tRBM3 cells show increases in SP percentage following Dox 
induction of RBM3. Flow cytometry dot plots of DCV fluorescence in HCT 116-
tRBM3 cells following 72 hours of induction with indicated concentration of 
Dox. Verapamil treatment was used as a pan efflux inhibitor to localize side 
population. Percentages represent fraction of whole, single and viable cells within 
the side population region. Error bars represent SEM. P values shown are 
obtained with Student’s t-test. 
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Figure 10: HCT 116-tRBM3 cells show decreased ADM uptake upon RBM3 
overexpression. Intracellular fluorescence following 30 minutes of treatment with 
indicated concentrations of ADM normalized to total sample protein. RBM3 
induction was generated with 500 ng/mL Dox for 72 hours. Graphs show mean 
with SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 11: HCT 116-tRBM3 cells show increased ADM efflux upon RBM3 
overexpression. Extracellular fluorescence following 325 µM ADM treatment for 
2 hours then efflux into fresh PBS for the indicated time. PBS fluorescence was 
measured for ADM concentration and normalized to total sample protein. RBM3 
induction was generated with 500 ng/mL Dox for 72 hours. Graphs show mean 
with SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
79
Figure 12
10
0
10
1
10
2
10
3
10
40
1022
PE
0 ng/mL Dox
10
0
10
1
10
2
10
3
10
40
615
PE
500 ng/mL Dox
HCT 116 tRBM3-1 
80
 
Figure 12: HCT 116-tRBM3-1 overexpressing RBM3 show a distinct population 
of ADM low cell after allowing for efflux. Cells were treated with Dox at the 
indicated concentrations for 72 hours. Histogram represents intracellular ADM 
fluorescence in whole, single cells following treatment with 40 µM ADM and 2 
hours of efflux into fresh DMEM.  
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Figure 13: RBM3 overexpression generates an increase in MRP2 and Pgp 
mRNA levels. Real time RT-PCR analysis of Pgp and MRP2 mRNA following 
500 ng/mL Dox treatment for the specified amount of time. mRNA fold change is 
normalized to 0 hour control. Graphs show mean fold change with SEM. *P < 
0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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HCT 116 Tet-RBM3 clones were induced for 72 hours with 500 ng/mL Dox and then treated 
with increasing concentrations of the two compounds. There was significantly higher level of 
survival of RBM3 overexpressing cells, especially at higher concentrations of paclitaxel (Figure 
14). HCT 116 Tet-RBM3 clones were induced for 72 hours with 500 ng/mL Dox and then 
treated with increasing concentrations of the two compounds. There was significantly higher 
level of survival of RBM3 overexpressing cells, especially at higher concentrations of paclitaxel 
(Figure 14). 
We also observe that the RBM3 induction is a dose depenent effect as induction of RBM3 using 
100 ng/mL of Dox shows a moderate increase in resistance. There was also a small portion of 
cells that appeared resistant to ADM treatment (Figure 15). As expected, uninduced RBM3 cells 
showed no appreciable difference between GFP vector controls or parental cells in either 
paclitaxel or ADM treatment (Figures 14 - 16). These data suggest that RBM3 overexpression 
increases stem cells within colon cancer cells and alters sensitivity to chemotherapies. The 
studies are further confirmation of previous studies that correlated RBM3 knockdown with loss 
of resistance to ADM and cisplatin (Zeng et al., 2009). 
We next characterized the relationship between RBM3 and spheroid formation. Interestingly, we 
observed that expresion of RBM3 protein within spheroids is higher than levels within 
monolayer cell cultures (Figure 17). This was observed in both DLD-1 and HCT 116 cells. This 
implies a correlative relationship between RBM3 expression and spheroid formation. We next 
determined whether RBM3 expression in monolayer culture could alter spheroid formation 
capacity. Following 72-h Dox induction in both DLD-1 and HCT 116 cells expressing vector 
control or RBM3, cells were plated into ultra-low attachment conditions and allowed to form 
spheroids. Both DLD-1 RBM3 and HCT 116 RBM3 overexpressing cells showed increased 
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Figure 14: RBM3 overexpression generates resistance to paclitaxel treatment. 
Hexoseaminidase assay following 72 hour induction with 100 or 500 ng/mL Dox 
followed by 48 hour treatment with paclitaxel in GFP or RBM3 overexpressing 
cells. Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001 for RBM3-
1, † P < 0.05, ††P < 0.01, †††P < 0.001 for RBM3-4 (Student’s t-test) 
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Figure 15: RBM3 overexpression generates resistance to ADM treatment. 
Hexoseaminidase assay following 72 hour induction with 100 or 500 ng/mL Dox 
followed by 48 hour treatment with ADM in GFP or RBM3 overexpressing cells. 
Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001 for RBM3-1, † P 
< 0.05, ††P < 0.01, †††P < 0.001 for RBM3-4 (Student’s t-test) 
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Figure 16: Uninduced RBM3 cells or GFP overexpressing cells show no 
significant resistance to either paclitaxel or ADM compared to parental controls. 
Hexoseaminidase assay following 72 hour induction with 100 or 500 ng/mL Dox 
followed by 48 hour treatment with ADM in GFP or RBM3 overexpressing cells. 
Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001 for RBM3-1, † P 
< 0.05, ††P < 0.01, †††P < 0.001 for RBM3-4 (Student’s t-test) 
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Figure 17: Spheroid formation induces RBM3 expression in DLD-1 and HCT 
116 cells. Western blot analysis of RBM3 expression in monolayer culture of 
HCT 116 and DLD-1 cells compared to cells cultured in spheroid conditions for 
14 days. 
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spheroid formation compared to vector or RBM3 uninduced controls (Figure 18). These data 
demonstrate that colorectal cancer cells increase RBM3 expression in the process of spheroid 
formation and that RBM3 is capable of enhancing spheroid formation capacity. Taken together, 
these data suggest that RBM3 overexpression enhances “stemness” in cancer cells.  
To further validate the model of RBM3 induced colon CSCs, we next studied the expression of 
both DCLK1 and LGR5 both HCT 116 and DLD-1 cells. As previously described DCLK1 and 
LGR5 are important markers for both ISCs and CSCs (Barker et al., 2009; Barker et al., 2007; 
May et al., 2008; Nakanishi et al., 2013). Following maximal induction of RBM3 with 500 
ng/mL Dox for 72 hours, we measured significant increases in the DCLK1+, LGR5+ and double 
positive populations in HCT 116 compared to uninduced control (Figure 19). Additionally, we 
measured increases in the LGR5+ and double positive populations with only a modest increase in 
DCLK1+ (P=.08) in DLD-1 cells compared to uninduced controls (Figure 20). We propose that 
the modest increase in DCLK1 expression in DLD-1 cells is due to DCLK1+ cells co-expressing 
LGR5 leading to most of the increase in DCLK1 expression being counted in the double positive 
population.  
As an additional marker of the stem cell population, we next measured changes in the 
CD44Hi/CD24Lo population. Previous studies have demonstrated that CD44Hi/CD24Lo population 
of cells display characteristics of CSCs (Mani et al., 2008). Following RBM3 induction, HCT 
116 Tet-RBM3 cells showed an increase in CD44Hi/CD24Lo compared to uninduced controls 
(Figure 21). GFP vector controls showed no appreciable difference following Dox induction 
(Figure 22). Previous reports have also shown that RBM3 overexpression induces alternative 
splicing of CD44 increasing the tumor suppressing variant of CD44 (CD44s) while suppressing 
levels of the pro-oncogenic CD44 variants (CD44v) in prostate cancer cells (Zeng et al., 2013). 
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Figure 18: RBM3 overexpression generates increased spheroid formation 
capacity in HCT 116 and DLD-1 cells. (A) Representative composite image of 
HCT 116 GFP or RBM3 inducible cells induced for 72 hours with 0 or 500 
ng/mL of Dox then plated in ultra-low attachment plates with colonosphere 
media and allowed to form spheroids for 14 days. (B) Quantification of spheroid 
assay as performed by Celligo embryoid body counting system. Bar graph shows 
spheroid number from 2,500 seeded cells. Error bars represent SEM. P values 
shown are obtained with Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001 
(Student’s t-test). 
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Figure 19: RBM3 overexpression in HCT 116 cells increases the percentage of 
DCLK1+, LGR5+ and double positive cells. Representative flow cytometry dot 
plot of HCT 116-tRBM3 cells stained for DCLK1 (PE) and LGR5 (AF647) 
following induction with 500 ng/mL Dox for 72 hours. Bar graphs below 
represent percentage of DCLK1 positive, LGR5 positive and DCLK1+/LGR5+ 
double positive populations. Error bars represent SEM. P values shown are 
obtained with Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-
test). 
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Figure 20: RBM3 overexpression in DLD-1 cells increases the percentage of 
LGR5+ and DCLK1/LGR5 double positive cells. Representative flow cytometry 
dot plot of DLD-1-tRBM3 cells stained for DCLK1 (PE) and LGR5 (AF647) 
following induction with 500 ng/mL Dox for 72 hours. Bar graphs below 
represent percentage of DCLK1 positive, LGR5 positive and DCLK1+/LGR5+ 
double positive populations. Error bars represent SEM. P values shown are 
obtained with Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-
test). 
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Figure 21: RBM3 overexpression in HCT 116 cells increases the percentage of 
CD44
Hi
/CD24
Lo
 cells. Representative flow cytometry dot plot of HCT 116-
tRBM3 cells stained for CD24 (PE) and CD44 (APCF) following induction with 
500 ng/mL Dox for 72 hours. Bar graphs below represent percentage of 
CD44
Hi
/CD24
Lo
 cells populations. Error bars represent SEM. P values shown are 
obtained with Student’s t-test. 
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Figure 22: GFP overexpression in HCT 116 cells generates no significant change 
in the percentage of CD44
Hi
/CD24
Lo
 cells. Representative flow cytometry dot 
plot of HCT 116-tGFP cells stained for CD24 (PE) and CD44 (APCF) following 
induction with 500 ng/mL Dox for 72 hours. Bar graphs below represent 
percentage of CD44
Hi
/CD24
Lo
 cells populations. Error bars represent SEM. P 
values shown are obtained with Student’s t-test. 
103
 
In HCT 116 Tet-RBM3 cells, RBM3 induction showed significant increases in both major 
isoforms of CD44 with no significant changes in GFP vector controls (Figure 23). This 
implicates RBM3 overexpression as inducing CD44 expression at the level of transcriptional 
changes. Additional studies are required to determine whether the CD44Hi/CD24Lo also 
overexpress DCLK1 and LGR5. Also additional studies may also be necessary for validating the 
DCLK1 and LGR5 positive population correlate with the spheroid forming and SP cells. 
Nevertheless, taken together, these data provide evidence that RBM3 overexpression is capable 
of increasing the CSC population as measured by multiple methods.  
 
Discussion 
Following the characterization of the Dox inducible RBM3 induction, we observed that HCT 116 
cells seemingly show less overall GFP fluorescence in GFP-RBM3 cells compared to GFP as 
read on a fluorimeter. This observation raises the possibilities that either RBM3 induction is less 
easily facilitated upon Dox treatment compared to GFP, RBM3 undergoes more rapid 
degradation than GFP resulting in lower steady-state levels or the focal localization of RBM3 
results in less overall fluorescence read. Furthermore, it appears that RBM3 expression, as 
visualized by the GFP-RBM3 fusion protein, is not as previously described by antibody 
reactivity based localization (Jogi et al., 2009). This finding implies that there may be exogenous 
factors that affect the localization of RBM3 and thereby affects its overall cellular function. One 
previous study has shown that RBM3 can undergo alternative splicing to exclude a single exon 
from the open reading frame resulting in more cytoplasmic localization (Smart et al., 2007). As 
this inducible fusion protein has such well controlled dosage and time dependence with Dox, it 
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Figure 23: RBM3 overexpression generates increases in both standard and 
variant isoforms of CD44 in HCT 116 cells. Western blot analysis for CD44 
following 72 hours of induction with 500 ng/mL Dox in HCT 116-tGFP or HCT 
116-tRBM3 cells. 
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may prove an ideal tool to pursue additional studies of RBM3 such as steady state levels, dose 
dependent pleiotropic effects and nuclear-cytoplasmic shuttling. 
These studies also show numerous pieces of evidence implicating RBM3 as being capable of 
inducing stem cell characteristics in colon cancer cells. Previous studies have shown that RBM3 
is upregulated within HSCs following treatment with GM-CSF; however, no evidence was 
presenting implicating RBM3 as the causative factor. Additionally, RBM3 has been previously 
demonstrated to confer resistance to classical chemotherapeutic agents cisplatin and ADM (Zeng 
et al., 2009). However, no clear mechanism was demonstrated regarding this chemoresistance. 
Our current study further confirms RBM3-induced chemoresistance to these agents and to 
paclitaxel. Our study also reveals a potential mechanism by which RBM3 is capable of 
increasing chemoresistance by inducing a SP of cells with high xenobiotic efflux capacity. It is 
interesting to note that while ADM and paclitaxel are both substrates of the ATP-binding cassette 
transporters, which are upregulated in the SP, cisplatin is not, but could be effluxed as a 
glutathione-cisplatin complex that may explain the fact that RBM3 knockdown sensitizes to 
cisplatin in prostate cancer (Ishikawa and Ali-Osman, 1993; Zeng et al., 2013). 
It is also important to note that in all cases of quantification of stem cell induction, the DLD-1 
cell line showed much higher endogenous stem cell activity. For example, SP assays 
demonstrated that DLD-1 cells show 4.5% SP cells compared to 0.08% in HCT 116. Spheroid 
formation for DLD-1 cells is approximately 14 spheres per 1,250 cells compared to 
approximately 10 spheres in HCT 116. Finally, DLD-1 cells showed higher populations of 
endogenous DCLK1+, LGR5+ and double positive populations. However, following RBM3 
induction, the magnitude of difference was significantly higher in all three assays for HCT 116. 
It is possible that DLD-1 cells show higher endogenous stem cell signaling activity through some 
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mechanism inherent mutational status while HCT 116 cells lack that similar genotype. It is also 
possible that this mechanism is the route by which RBM3 induction causes “stemness” thereby 
generating rather large changes in HCT 116 cells following RBM3 induction compared to 
changes induced in DLD-1. 
Furthermore, a significant question arises regarding stem cell marker expression in RBM3 
overexpressing cells. It appears that RBM3 overexpression in both DLD-1 and HCT 116 induces 
an increase in the DCLK1/LGR5 double positive population. While previous studies have shown 
that DCLK1+ and LGR5+ cells occupy separate niches within normal intestinal epithelium, there 
is currently very little evidence investigating the co-expression of DCLK1 and LGR5 in colonic 
CSCs (Barker et al., 2007; May et al., 2008). Additionally, LGR5 expression has been shown to 
be driven primarily by Wnt/β-catenin signaling; however, no current studies have elucidated a 
regulatory factor promoting the expression of DCLK1 in the intestine. If RBM3 is inducing 
“stemness” correlated with DCLK1 expression, further studies of the RBM3 induced stem cell 
model may elucidate a signaling mechanism that regulates the expression of DCLK1 at the 
transcriptional level. 
Here we propose a model where tumor formation and RBM3 expression are intertwined. 
Additionally, we show a potential mechanism through which RBM3 overexpression can lead to 
initiation of colorectal cancer through expansion of the stem cell compartment. Finally, while it 
is clear that RBM3 induction creates a significant increase in the stem cell population further 
studies are required to elucidate if the increased stem cell population arises through an increase 
in self-renewal of the existing stem cell population or through inducing an increase in plasticity 
of the proliferative progeny generating a de-differentiated cell. 
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Chapter III: RBM3 overexpression generates an increase in β-catenin signaling 
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Introduction 
The β-catenin signaling cascade is one of the most critical factors driving the self-renewal of the 
ISC compartment in the intestinal epithelium (Korinek et al., 1998). Overactivation of β-catenin 
transcription is also the driving force for intestinal tumorigenesis and tumor progression in 
colorectal cancers. This is best exemplified by the fact that the majority of colorectal cancers 
contain an inactivating mutation of the APC tumor suppressor or activating mutations of β-
catenin itself (Fearon and Vogelstein, 1990; Morin et al., 1997). These mutations lead to loss of 
appropriate regulation and overstabilization of β-catenin leading to increased nuclear β-catenin 
accumulation and subsequently transcription of genes that drive various programs resulting in 
increased proliferation and multidrug resistance (Flahaut et al., 2009; Noda et al., 2009; Reya 
and Clevers, 2005). While the majority of cancers show dysregulation of β-catenin signaling, 
there is heterogeneity in the level of nuclear β-catenin implying intratumoral variation in β-
catenin transcriptional activity. It is theorized that the pleotropic effects of β-catenin signaling 
can be related to the fact that β-catenin activated transcriptional programs show dosage 
dependence to nuclear β-catenin (Gaspar and Fodde, 2004). As many of the clinically relevant 
characteristics of colorectal cancers are so heavily dependent upon β-catenin signaling, it 
becomes important to identify novel factors that modulate the activity of this pathway. 
Our previous studies have revealed a role for RBM3 in inducing the stem cell phenotype within 
colorectal cancers. In order to elucidate a molecular signaling pathway for the RBM3 induced 
stem cell phenotype, here we investigate the β-catenin signaling pathway following RBM3 
overexpression. We focused our studies on the Wnt/β-catenin pathway because both CD44 and 
LGR5 have been identified as β-catenin transcriptional targets (Barker et al., 2007; Kanwar et al., 
2010; Wielenga et al., 1999). Moreover, β-catenin signaling activity has been shown to be 
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essential for SP cells and spheroid formation (Chikazawa et al., 2010; Kanwar et al., 2010). We 
demonstrate that RBM3 is capable of increasing the levels of nuclear β-catenin correlating with 
an overall increase in β-catenin transcriptional activity. Additionally, we show that RBM3 
induction also increases AKT activity to inhibit the activity of the destruction complex member, 
GSK3β. We also show that this decreased GSK3β activity is correlated with a decrease in 
phosphorylation in β-catenin activity following RBM3 overexpression. Additionally, 
pharmacologic inhibition of GSK3β using BIO phenocopies the RBM3 induced β-catenin 
signaling phenotype. We demonstrate that RBM3 is a novel factor for the induction of the β-
catenin signaling cascade in colorectal cancer cells which implies a mechanism for the RBM3 
induced stem cell phenotype. 
 
Materials and Methods 
 
Cell culture 
HCT 116 and DLD-1 cell lines were obtained from ATCC and cultured under conditions of 5% 
CO2 in DMEM (Corning) containing 10% FBS (Sigma-Aldrich) and 1% antibiotic/antimycotic 
solution (Corning). Following transduction of viruses cells were continually cultured in 1 mg/mL 
G 418 (Santa Cruz Biotechnology) and/or 1µg/mL puromycin (Life Technologies) as relevant. 
 
Lentivirus propagation and infection 
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DLD-1 and HCT 116 tGFP and tRBM3 cells were generated as described in Chapter II. 
Additionally, DLD-1 and HCT 116 CMV-Gus and CMV-RBM3 plasmids were generated using 
the Gateway cloning system according to manufacturer recommendations (Life Technologies). 
The plasmids were recombined into lentiviral overexpression plasmids obtained from Addgene 
(Campeau et al., 2009). 
Lenti-X cells were obtained from Dr. Roy Jensen and were used to generate virus. Lenti-X cells 
were transfected with 7.5 µg of each of the pGIPZ packaging plasmids obtained from Dr. Roy 
Jensen as well as 24 µg of the cargo vector using Lipofectamine 2000 (Life Technologies). Viral 
supernatant was collected at 48, 72 and 96 hours following lipofectamine transfection, pooled, 
clarified through a 0.45 µm syringe filter and concentrated using the Lenti-X concentrator 
(ClonTech Laboratories, Inc.).  
HCT 116 and DLD-1 cells were transduced in suspension with 4 µg/mL polybrene (Sigma 
Aldrich). 24 hours following transduction, fresh media was added and following 48 hours of 
transduction puromycin selection media was added. Parental cells were cultured alongside 
transduced cells for 1 week under similar selection antibiotics to ensure that no untransduced 
cells survived following the 1 week of selection under gross inspection by microscopy.  
 
Western blotting 
Western blot were performed using poly-acrylamide gel electrophoresis within a Miniprotean 
Tetracell apparatus (BioRad) followed by blotting onto 0.45 µm pore size Immobilon polyvinyl 
difluoride membrane (Millipore) using a mini Transblot module (BioRad). Antibodies for RBM3 
were obtained from AbCam (AbCam) or custom generated through Fisher (Thermo Fisher 
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Scientific). Antibodies for β-catenin and phospho-β-catenin were obtained from Cell Signaling 
(Cell Signaling Technology) or BD Biosciences (BD Biosciences). Antibodies for GSK3β and 
phospho-GSK3β were obtained from Cell Signaling (Cell Signaling Technology). 
 
Nuclear fractionation 
Nuclear cytoplasmic extraction was generated through NE-PER kit (Thermo Fisher Scientific, 
Rockford, IL, USA) according to manufacturer recommendations. GAPDH antibody (Cell 
Signaling Technology) was used for cytoplasmic loading control and Lamin A/C antibody (Cell 
Signaling Technology) was used for nuclear loading control. Both loading controls were 
evaluated for each fraction to validate minimal cross-contamination of each compartment. 
 
Immunofluorescence and immunohistochemistry 
For immunofluorescence (IF), cells were plated on sterile glass cover slips with appropriate 
treatments. Cells were then fixed using neutral buffered formalin then permeablized using 0.1% 
Triton. Antigen blocking was achieved using 1% bovine serum albumin in PBS. Cells were 
incubated with primary antibody overnight at 4°C followed by staining with fluorophore 
conjugated secondary antibody for 1 hour at room temperature. Coverslips were mounted using 
Prolong Gold with DAPI (Life Technologies, Grand Island, NY, USA).  For IHC, spheroids 
were embedded in paraffin blocks and slides were obtained with 5µm sections. Slides were 
deparaffinized then boiled for 20 minutes in antigen retrieval buffer (10 mM sodium citrate, pH 
6, 0.05% Tween-20) followed by peroxidase quenching using Peroxabolish (Biocare Medical, 
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Concord, CA, USA). Slides were then stained using Histostain SP kit (Life Technologies) as per 
manufacturer recommendations. Antibodies used were the same as those used for western blots. 
 
Wound healing assay 
Cells were plated and allowed to reach confluency so that Dox induction was present for the 
indicated amount of time. Confluent cells were scratched and images were taken. Images were 
taken at the same spot at each indicated time point for each sample. Images were processed by 
ImageJ software (National Institutes of Health) to quantify number of total pixels in the wound 
area. Migration at each time point was calculated as the difference in the number of pixels of 
wound area at time 0 to the number of pixels at that time point. 
 
Real time RT-PCR 
Total cellular RNA was isolated using TRIzol reagent followed by reverse transcription using 
SuperScript II in the presence of random hexonucleotide primers (Life Technologies, Grand 
Island, NY, USA). cDNA was then analyzed by real-time RT-PCR using Jumpstart Taq 
polymerase (Sigma Aldrich, St. Louis, MO, USA) and SYBR Green nucleic acid stain (Life 
Technologies, Grand Island, NY, USA). Threshold crossing values for each gene were 
normalized to GAPDH gene expression. mRNA expression was then normalized to fold change 
relative to uninduced controls. Primers used in this study are as follows: 
CD44: 5’- AACAGTCCTGTGACTCAACTCAAG-3’ / 5’-
TTAGAGACATGGGACAAATGCCAC-3’ 
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c-MYC: 5’-CACACATCAGCACAACTACGCA-3’ / 5’-TTGACCCTCTTGGCAGCAG-3’ 
GAPDH: 5’-CAGCCTCAAGATCATCAGCA-3’ / 5’-GTCTTCTGGGTGGCAGTGAT-3’ 
LGR5: 5’-TGGCACCCGCTATGTCCAG -3’ / 5’-GTAGCAGGGATTCTGTCTG -3’ 
 
TOPFlash assay 
TOPFlash and FOPFlash β-catenin luciferase reporter plasmids were generously provided by Dr. 
Shahid Umar. Cells were plated in 24 well plates in antibiotic/antimycotic free medium and 
without selection antibiotics. Each well was transfected using 2 µL of Lipofectamine 2000 (Life 
Technologies) complexed with 900 ng of TOPFlash luciferase plasmid and 100 ng of CMV 
renilla luciferase plasmid. 8 hours following transfection, the media was replaced with normal 
growth medium containing selection antibiotics and appropriate treatments. Luciferase activity 
was then read using the dual-luciferase reporter assay system (Promega, Madison, WI, USA) on 
a plate reader. TOPFlash luciferase activity was normalized to CMV renilla luciferase activity.  
 
siRNA transfection 
siRNA for CTNNB1 (siCTNNB1) and scrambled siRNA (siSCR) were purchased from Life 
Technologies. Cells were plated in 6-well plates and allowed to adhere overnight. Cells were 
then transfected with either siCTNNB1 or siSCR using Lipofectamine RNAiMAX (Life 
Technologies) according to manufacturer specifications. 25 pmol of siRNA was added per well. 
Cells were treated with appropriate concentrations of Dox and were assayed 72 hours following 
transfection. 
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SP assay 
SP assay was performed as previously described with minor modifications (Mathew et al., 
2009). In brief, cells were plated at 100,000 cells/mL into 6 well plates with relevant treatments. 
Following 72 hours of treatment cells were trypsinized and resuspended at 1 million cells/mL in 
DMEM and pre-warmed for 15 minutes at 37°C. Cells were then given 50 µM verapamil (Sigma 
Aldrich), as a pan efflux inhibitor, or vehicle for 30 minutes. Cells were then incubated with 10 
µM Vybrant DyeCycle Violet (DCV) (Life Technologies) for 90 minutes at 37°C. Cells were 
then resuspended in ice cold SP buffer containing 2% FBS, 2 mM HEPES, 1 µg/mL 7-amino 
actinomycin D (7AAD) (Life Technologies) in Hank’s balanced salt solution and analyzed on a 
BD LSR II for SP. DCV was excited using a violet diode laser (408 nm) and emission was 
measured with a 450/50 nm bandpass filter (DCV Blue) and 630 nm longpass, 660/40 nm 
bandpass filter (DCV Red). Viability gating was established with 7AAD with excitation at 552 
nm and emission monitored with a 630 nm longpass, 660/40 nm bandpass filter. Cells were 
initially gated for appropriate size using the side scatter (SSC) and forward scatter (FSC). Cells 
were then gated for viability using 7-AAD uptake to eliminate non-viable cells. Finally, the 
location of the SP gate was established using the verapamil treated sample. 
 
Stem cell marker flow cytometry 
Cells were treated with Dox to induce expression of GFP or RBM3 for 72 hours. Cells were then 
trypsinized then resuspended at 1x106 cells. For DCLK1 and LGR5, cells were stained with 
Alexafluor 647 (AF647) conjugated LGR5 antibody (BD Biosciences) or PE conjugated DCLK1 
antibody (AbCam) according to manufacturer recommendations. PE conjugation was performed 
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using the Zenon PE labelling kit (Life Technologies) according to manufacturer 
recommendations. 
 
Treatments 
(2’Z,3’E)-6-Bromoindirubin-3′-oxime (BIO) and N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT) were purchased from Sigma-Aldrich. N-[2-(Cyclohexyloxy)-
4-nitrophenyl]methanesulfonamide (NS-398) was generously donated by Dr. Dan Dixon. 
 
Results 
We initiated these studies by examining levels of total and nuclear β-catenin in RBM3 
overexpressing cells. Following RBM3 induction in DLD-1 and HCT 116 cells, a moderate 
increase in total β-catenin levels was observed after 72 hours of 500 ng/mL Dox induction 
(Figure 1). Interestingly, analysis of multiple clones constitutively overexpressing RBM3 in 
HCT 116 and DLD-1 cells showed a more prominent increase in total β-catenin (4.12-fold vs 
1.60-fold increase in HCT 116 and 2.05-fold vs 1.44-fold in DLD-1) compared to inducible 
RBM3 expression (Figure 2). One possibility to account for this comparative increase is that the 
time frame of RBM3 overexpression lends to a more prominent induction of β-catenin levels. 
However, as most previous studies have been carried out in RBM3 inducible heterogeneous 
populations, we chose to continue these studies in the same cell lines to maintain consistency.  
As β-catenin transcriptional activity depends upon its localization to the nucleus, we next 
examined changes in β-catenin levels in the cytoplasm and nucleus following 72 hour Dox 
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Figure 1: DLD-1 and HCT 116-tRBM3 cells show increases in total β-catenin 
following RBM3 induction. Western blot analysis of β-catenin in DLD-1 and 
HCT 116 tGFP or tRBM3 cells with indicated concentrations of and times of Dox 
induction. β-catenin levels show significant elevation at 500 ng/mL Dox for 72 
hours. Densitometry represents fold change of total β-catenin relative to 
uninduced tRBM3 cells normalized to GAPDH. Error represents SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 2: Constitutive RBM3 overexpression significantly increases β-catenin 
levels. Western blot analysis of β-catenin in DLD-1 and HCT 116 CMV-RBM3 
cells or vector control following clonal selection. HCT 116 CMV-RBM3 and 
DLD-1 CMV-RBM3 clones show significant upregulation of total β-catenin 
following RBM3 overexpression for greater than one week. Densitometry 
represents fold change of total β-catenin relative to vector control group 
normalized to Actin. Error represents SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
(Student’s t-test). 
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induction. RBM3 overexpression did not significantly affect cytoplasmic levels of β-catenin 
(Figure 3). However, nuclear levels of β-catenin were increased upon RBM3 overexpression in 
both DLD-1 and HCT 116 compared to uninduced or vector controls (Figure 3). Interestingly, 
levels of nuclear β-catenin were elevated in uninduced RBM3 cells compared to uninduced GFP 
vector control implying that due to the slight leakiness of the Tet-ON system, the mild induction 
of RBM3 may also elevate nuclear β-catenin. Additionally, IF labeling revealed nuclear 
accumulation of β-catenin in RBM3 overexpressing cells, while membrane localization of β-
catenin showed no significant difference (Figure 4). This effect was further replicated with IHC 
of spheroids (Figure 5). Here we also note that observed localization of GFP-RBM3 is similar to 
RBM3 alone and that this was not an effect of the GFP tag on RBM3. IF staining of RBM3 in 
tRBM3 cells confirms that untagged RBM3 also primarily localizes at the nucleolus in DLD-1 
and HCT 116 cells. 
Since increased nuclear β-catenin is associated with loss of E-cadherin and EMT, we also 
determined whether RBM3 overexpression induces a similar change in colon cancer cells 
(Brabletz et al., 1998; van der Wurff et al., 1997). Our initial induction of RBM3 for 72 hours 
showed no significant changes in EMT as measured by wound healing. As other studies suggest 
that the molecular programming to induce EMT could take up to 2 weeks, we decided to 
continually induce RBM3 for a similar time period and measure wound healing capacity (Mani 
et al., 2008). We observed significant increases in wound healing following 12 days of Dox 
induction; however, no significant differences were observed at 9 days or less of Dox induction 
(Figure 6). This also raises the possibility that many phenotypic effects exerted by RBM3 could 
require extended periods of expression to see an effect. This is similarly validated by the 
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Figure 3: RBM3 overexpression significantly increases levels of nuclear β-
catenin. Western blot analysis of nuclear and cytoplasmic extracts of HCT 116 
and DLD-1 tGFP and tRBM3 cells. GAPDH and Lamin A/C are used as a 
loading controls for the cytoplasmic and nuclear fractions, respectively. β-catenin 
was primarily increased in the nuclear fraction upon RBM3 overexpression using 
500 ng/mL Dox for 72 hours. Densitometry represents fold change of β-catenin 
relative to uninduced tRBM3 cells normalized to GAPDH for cytoplasmic 
extracts and Lamin A/C for nuclear extracts. Error represents SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 4: Cells with high levels of RBM3 show increased nuclear localization of 
β-catenin. Immunofluorescent microscopy of DLD-1 and HCT 116 tRBM3 cells 
following 72 hours of induction with indicated concentrations of Dox. Cells with 
high RBM3 also appear to contain increased levels of nuclear β-catenin. 
Regardless of RBM3 expression, levels of membrane associated β-catenin appear 
unchanged.  
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Figure 5: RBM3 overexpression enhances β-catenin nuclear localization in 
spheroids. IHC of β-catenin and RBM3 in HCT 116 tGFP or tRBM3 spheroids. 
Spheroids were grown for 14 days with 500 ng/mL Dox to induce GFP or RBM3 
overexpression, then fixed and sectioned. 
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Figure 6: RBM3 overexpression generates increases in wound healing. (A) Cells 
were treated with indicated concentration of Dox for 10 days. Cells were then 
plated into 6 well plates with indicated concentrations of Dox and reached 
confluency at 12 days. Figure representsphase contrast microscopy of wound 
healing at 0 hours and 24 hours following after creation of wound. Red outline 
represents wound area in pixels as calculated by ImageJ software. (B)  Line graph 
of time dependent wound healing following 500 ng/mL induction with Dox for 
indicated time. Wound healing is calculated as difference in number of pixels of 
wound at time compared to 0 hours. Error bars show SEM. *P < 0.05, **P < 
0.01, ***P < 0.001 (Student’s t-test). 
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observation that RBM3 overexpression for multiple weeks using constitutive overexpression 
generates much higher increases in β-catenin levels (Figure 2). 
To validate that the increase in nuclear β-catenin levels correlates with increased transcriptional 
activity, we examined TOPFlash luciferase assay. The TOPFlash reporter plasmid encodes 
multiple copies of the TCF-1 consensus sequence driving a firefly luciferase gene and is a widely 
used reporter of β-catenin/TCF transcriptional activity (Korinek et al., 1997; van de Wetering et 
al., 1991). Following 48 hour RBM3 induction, TOPFlash luciferase activity, normalized to 
CMV/Renilla luciferase was significantly increased in both cell lines (Figure 7). Further 
confirmation of increased β-catenin transcriptional activity was observed through elevated levels 
of its target genes c-MYC, LGR5 and CD44 as well as c-MYC protein. (Barker et al., 2007; He et 
al., 1998; Wielenga et al., 1999) (Figure 8). 
We have previously shown that RBM3 overexpression increases SP fraction and LGR5+ cells in 
HCT 116-tRBM3 and DLD-1-tRBM3 cells (Chapter 2, Figures 8, 9, 19 & 20). Furthermore, 
previous studies have shown that LGR5 expression and the SP fraction are dependent on β-
catenin signaling (Barker et al., 2007; Chikazawa et al., 2010). Accordingly, we next wanted to 
investigate the dependence of RBM3 induced stem cell characteristics on β-catenin 
transcriptional activity. We first validated that siRNA to CTNNB1 (siCTNNB1) would reliably 
decrease β-catenin expression (Figure 9). Next we measured changes in the percentage of 
LGR5+ and DCLK1+ in DLD-1-tRBM3 cells in the context of RBM3 overexpression and β-
catenin knockdown. We observe that scrambled siRNA (siSCR) appears to have no effect on 
RBM3 induced LGR5 expression (Figure 10). However, following knockdown of β-catenin we 
observe an abrogation of the LGR5+ population which cannot be rescued with RBM3 
overexpression (Figure 10). siCTNNB1 shows a similar effect on the SP fraction which also 
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Figure 7: RBM3 overexpression generates increased β-catenin transcriptional 
activity. DLD-1 and HCT 116 tRBM3 cells induced for 48 hours at 500 ng/mL 
Dox with transient transfection of TOPFlash firefly luciferase and CMV renilla 
luciferase plasmids. Bar graphs represent firefly luciferase luminescence 
normalized to renilla luciferase luminescence. Error bars represent SEM. P values 
shown are obtained with Student’s t-test. 
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Figure 8: RBM3 overexpression generates increases in β-catenin transcriptional 
targets. (A) Real time RT-PCR and western blot analysis of c-MYC showing 
following Dox induction for 72 hours. (B) Real time RT-PCR of CD44 and 
LGR5 following Dox induction for 72 hours. Bar graphs represent fold change 
relative to control. Error bars represent SEM. P values shown are obtained with 
Student’s t-test. Densitometry represents fold change of c-MYC relative to 
uninduced tRBM3 cells normalized to GAPDH. Error represents SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 9: siCTNNB1 reliably knocks down β-catenin levels. Western blot 
analysis for total β-catenin in DLD-1-tRBM3 cells. Cells were transfected with 
either siSCR or siCTNNB1 for 72 hours then collected and analyzed. 
Densitometry represents fold change of β-catenin relative to siSCR transfected 
cells normalized to GAPDH. Error represents SEM. *P < 0.05, **P < 0.01, ***P 
< 0.001 (Student’s t-test). 
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Figure 10: RBM3 mediated increases in LGR5 expression are dependent upon β-
catenin. Representative flow cytometry dot plot of DLD-1-tRBM3 cells stained 
for DCLK1 (PE) and LGR5 (AF647) following induction with indicated 
concentrations of Dox and transfection with indicated siRNA for 72 hours. Bar 
graphs below represent percentage of LGR5 positive populations. Error bars 
represent SEM. P values shown are obtained with Student’s t-test. *P < 0.05, **P 
< 0.01, ***P < 0.001 (Student’s t-test). 
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cannot be rescued with RBM3 overexpression (Figure 11). This implies that the increases 
measured in SP fraction and LGR5 expression following RBM3 overexpression are dependent 
on an RBM3 mediated increase in β-catenin signaling.  
Interesting to note is that, DLD-1 cells show a higher basal TOPFlash activity with a more 
modest increase following RBM3 overexpression compared to HCT 116. HCT 116 cells 
showing an average of 28.3 ± 3.1 compared to 3.3 ± 0.13 in uninduced controls and DLD-1 
showing an average of 15.9 ± 0.79 compared to an average of 9.4 ± 0.52 in uninduced controls 
(Figure 7). We attribute this observation as well as the similar changes in SP population, 
spheroid formation and stem cell marker expression to the fact that DLD-1 cells encode a 
mutated APC whereas HCT 116 cells maintain intact wild type APC and at least one wild type β-
catenin allele (Yang et al., 2006). Based on these data, we propose that RBM3 increases β-
catenin transcriptional activity resulting in increased DCLK1+ and LGR5+ stem cell population 
thereby enhancing SP, spheroid formation and increasing β-catenin signaling activity. 
The relative difference in the increases in β-catenin activity in HCT 116 RBM3 cells compared 
to DLD-1 RBM3 cells implies the mechanism of RBM3 mediated β-catenin signaling may act at 
the level of β-catenin degradation. This result would suggest that a member of the destruction 
complex could be affected. We chose to investigate GSK3β as a target for RBM3 mediated β-
catenin activity because previous reports show that GSK3β is inactivated during hypoxia, and 
RBM3 expression is also induced following hypoxia (Mottet et al., 2003; Wellmann et al., 2004). 
We observed significant increases in inhibitory phosphorylation at serine position 9 in GSK3β 
(pS9 GSK3β) at 48 and 72 hours of RBM3 induction with 500 ng/mL Dox in HCT 116-tRBM3 
cells (Figure 12A). DLD-1-tRBM3 cells also showed a trend to increase levels of pS9 GSK3β 
(p=0.08) at 48 hours with 500 ng/mL Dox induction (Figure 12A). As expected, GFP vector 
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Figure 11: RBM3 mediated increases in SP fraction are dependent upon β-
catenin. (A) Real time RT-PCR and western blot analysis of c-MYC showing 
following Dox induction for 72 hours. (B) Real time RT-PCR of CD44 and 
LGR5 following Dox induction for 72 hours. Bar graphs represent fold change 
relative to control. Error bars represent SEM. P values shown are obtained with 
Student’s t-test. Densitometry represents fold change of c-MYC relative to 
uninduced tRBM3 cells normalized to GAPDH. Error represents SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 12: DLD-1 and HCT 116-tRBM3 cells show decreased GSK3β activity. 
(A) Western blot analysis of pSer9-GSK3β and GSK3β in DLD-1 and HCT 116 
tGFP or tRBM3 cells with indicated concentrations of and times of Dox 
induction. Cells show significant increases in levels of pSer9-GSK3β at 500 
ng/mL Dox induction for 72 hours. (B) Western blot analysis of p33/37/41-β-
catenin following 6 hour treatment with 5µM MG 132 showing decreased pβ-
catenin relative to total β-catenin following 500 ng/mL Dox induction for 72 
hours. Densitometry represents fold change of pS9 GSK3β or p33/37 β-catenin  
relative to uninduced tRBM3 cells normalized to total GSK3β or total β-catenin, 
respectively. Error represents SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
(Student’s t-test). 
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control showed no appreciable difference in GSK3β phosphorylation in either cell line (Figure 
12A). We next validated this increase in GSK3β phosphorylation by determining 
phosphorylation at serines 33 and 37, and threonine at position 41 in β-catenin. There was 
reduced phosphorylation in β-catenin in HCT 116 cells (Figure 12B) suggesting that GSK3β is 
inactivated. GSK3β phosphorylation can occur through either induction of Wnt signaling or 
through the action of activated AKT kinase (Dorsam and Gutkind, 2007) (Figure 13). In previous 
studies, we have demonstrated that RBM3 induces IL-8 mRNA and prostaglandin E2 (PGE2), 
both of which result in a phosphorylating activation of AKT (Chapter 2, Figure 5) (Sureban et 
al., 2008b). Accordingly, we determined whether AKT activity may explain attenuated GSK3β 
activity. RBM3 overexpression showed significant increases in AKT phosphorylation at serine 
473, whereas no appreciable increase was observed in vector controls or uninduced RBM3 cells 
(Figure 14). These data imply that RBM3 overexpression increases β-catenin activity by 
inhibiting GSK3β through the actions of activated AKT kinase. Interestingly, inhibition of COX-
2 using NS-398 did not significantly affect RBM3 induced β-catenin activity as measured by 
TOPFlash luciferase activity (Figure 15). This lack of change could be potentially explained by 
RBM3 induction of IL-8, as well as other currently unknown mRNA clients, which can act 
through similar mechanisms to induce AKT activation. This implies a potential need to validate 
this pathway using a dual inhibition of IL-8 and COX-2. 
Finally, the GSK3β inhibitor (2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO) has been shown to 
upregulate β-catenin signaling and increase the expression of ABC proteins (Liu et al., 2012; 
Meijer et al., 2003). BIO shows high specificity towards GSK3 kinase activity with an IC50 
measured at 5 nM compared to an IC50 of greater than 5 µM for other kinases such as protein 
kinase C family members, mitogen activated protein kinases, and cyclic-AMP dependent  protein 
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Figure 13: Model for RBM3 induced β-catenin signaling adapted from Dorsam 
and Gutkind. RBM3 overexpression has been shown to increase COX-2 and IL-8 
expression at the posttranscriptional level. PGE2 produced by COX-2 and IL-8 
can both act through G protein coupled receptors to activate PI3K and AKT. This 
in turn can suppress GSK3β allowing β-catenin to accumulate and induce 
transcriptional changes within the nucleus. 
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Figure 14: HCT 116 cells show increased AKT activity following RBM3 
overexpression. Western blot analysis of pS473 AKT and total AKT following 
induction for 72 hour with indicated concentrations of Dox. pS473 AKT levels 
are significantly elevated relative to total AKT with RBM3 overexpression. 
Densitometry represents fold change of pS473 AKT relative to uninduced tRBM3 
cells normalized to total AKT. Error represents SEM. *P < 0.05, **P < 0.01, 
***P < 0.001 (Student’s t-test). 
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Figure 15: COX-2 inhibition does not abrogate RBM3 induced β-catenin 
activity. HCT 116 tRBM3 cells induced for 48 hours at 500 ng/mL Dox with 
transient transfection of TOPFlash firefly luciferase and CMV renilla luciferase 
plasmids. Cells were also treated with 0 or 10 µM NS-398 for 48 hours. Bar 
graphs represent firefly luciferase luminescence normalized to renilla luciferase 
luminescence. Error bars represent SEM.  
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kinases (Meijer et al., 2003). We next examined the effects of pharmacologic GKS3β inhibition 
using BIO on RBM3 overexpressing cells. HCT 116 cells treated with BIO showed increase in 
both total and nuclear β-catenin levels similar to that of RBM3 overexpression (Figure 16). 
Additionally, BIO treatment induced c-MYC expression in both GFP and RBM3 overexpressing 
cells similar to RBM3 overexpression (Figure 17A). In addition, there was increased TOPFlash 
luciferase activity following BIO treatment (Figure 17B). Moreover, the combination of RBM3 
overexpression and BIO treatment generated an even more robust increase in β-catenin signaling 
as measured through total β-catenin, nuclear β-catenin, c-MYC protein expression and TOPFlash 
luciferase activity (Figures 16 & 17). These data further demonstrate that RBM3 regulates β-
catenin signaling pathway by affecting GSK3β activity. On the other hand, it also implicates a 
secondary signaling mechanism through which RBM3 may be acting. 
Notch signaling is another signaling cascade that ISCs rely on to maintain stem cell homeostasis 
(VanDussen et al., 2012). The transmembrane Notch receptor is activated upon binding with one 
of several ligands including those of the Jagged family or the Delta-like (DLL). Following 
binding, the extracellular portion of Notch is cleaved. Subsequently, the intracellular portion of 
the Notch receptor is cleaved by the γ-secretase complex allowing the Notch intracellular domain 
(NICD) to translocate to the nucleus, associate with transcription factors and induce 
transcriptional changes within the cell (Vooijs et al., 2011). Previous studies have demonstrated a 
significant amount of crosstalk between the β-catenin and Notch signaling cascades, with some 
studies showing that the two are mutually agonistic, while others suggest some level of 
antagonism between them (Kim et al., 2012a; Kwon et al., 2011; Nakamura et al., 2007). We 
therefore decided to examine whether Notch activation might play a role in RBM3 induced β-
catenin signaling. We observed that treatment with DAPT, a γ-secretase inhibitor used to 
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Figure 16: BIO treatment phenocopies RBM3 induced increases in β-catenin. 
(A) Western blot analysis of total β-catenin in HCT 116-tGFP and HCT 116-
tRBM3 cells following 72 hour treatment with indicated concentrations of Dox 
and BIO. (B) Western blot analysis of nuclear and cytoplasmic fractions of HCT 
116-tRBM3 cells following 72 hour treatment with indicated concentrations of 
Dox and BIO. BIO or RBM3 show similar increases in β-catenin. Combined 
RBM3 and BIO show a trend towards a further increase in total β-catenin. 
Densitometry represents fold change of total β-catenin relative to uninduced 
tRBM3 cells normalized to GAPDH for total cell lysate or cytoplasmic fraction 
and Lamin A/C for nuclear fraction. Error represents SEM. *P < 0.05, **P < 
0.01, ***P < 0.001 (Student’s t-test). 
154
Figure 17
++ --
+ +- -
Dox 500 ng/mL
BIO 100 nM
0
50
100
150
200
250
No
rm
al
ize
d 
Lu
ci
fe
ra
se
Ac
tiv
ity
 (A
rb
itr
ar
y 
Un
its
)
***
***
***
***
A
B
GAPDH
c-MYC
100 nM
500 ng/mL
H
C
T 
11
6
tGFP tRBM3
+- +-+- +-
- +- +- +- +
Dox
BIO
1.06
± .15
1.41
± .39
1.25
± .17
0.93
± .08
1.00 1.55
± .41
2.40
± .51
3.24
± 1.37
*
Densitometry
fold change
155
 
Figure 17: BIO treatment phenocopies RBM3 induced β-catenin transcriptional 
activity. (A) Western blot analysis for c-MYC protein in HCT 116 tGFP and 
tRBM3 cells following 72 hours of treatment with indicated concentrations of 
Dox and BIO. (B) HCT 116 tRBM3 cells treated for 48 hours at indicated 
concentrations of Dox and BIO with transient transfection of TOPFlash firefly 
luciferase and CMV renilla luciferase plasmids. Densitometry represents fold 
change of c-MYC relative to uninduced tRBM3 cells normalized to GAPDH. 
Error represents SEM. Bar graphs represent firefly luciferase luminescence 
normalized to renilla luciferase luminescence. Error bars represent SEM. *P < 
0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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suppress Notch activation, showed a minor increase in RBM3 induced β-catenin activity in 
DLD-1 cells, but showed no significant change in HCT 116 cells  (Figure 18A). Furthermore, 
overactivation of Notch1 through transient transduction of free N1ICD demonstrated an 
antagonistic effect in uninduced RBM3 cells that was present proportionally in RBM3 
overexpressing cells implying that Notch overactivation provides no significant effect on RBM3 
induced β-catenin activity in these two colon cancer cell lines (Figure 18B).  
 
Discussion 
In the previous chapter, we showed that RBM3 is capable of inducing an increase in the 
population of stem cells within colon cancer cells. Here, we report that RBM3 overexpression 
results in a profound increase in β-catenin transcriptional activity, which is a critical factor in 
maintaining stem cells in both normal intestine and colon cancer. Previous studies have 
implicated that RBM3 is upregulated in the stem cell compartment (Baghdoyan et al., 2000). 
However, this is the first study to demonstrate a mechanism through which RBM3 plays a role in 
maintaining stem cell self-renewal. Specifically, we show that RBM3 overexpression results in a 
significant increase in both total β-catenin and nuclear β-catenin with no significant increases in 
cytoplasmic β-catenin levels implying increases in transcriptionally active β-catenin. This 
observation correlates with decreased activity of GSK3β thereby inhibiting the β-catenin 
degradation pathway allowing it to accumulate, translocate to the nucleus and induce 
transcriptional changes. 
 
Our study also suggests that there must be a second mechanism by which RBM3 activates β-
catenin signaling as overexpression of RBM3 combined with inhibition of GSK3β was capable 
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Figure 18: RBM3 induced β-catenin transcriptional activity is independent of 
crosstalk with Notch signaling. (A) DLD-1 and HCT 116 tRBM3 cells treated for 
48 hours at indicated concentrations of Dox and DAPT with transient transfection 
of TOPFlash firefly luciferase and CMV renilla luciferase plasmids. (B) DLD-1 
and HCT 116 tRBM3 cells treated for 48 hours at indicated concentrations of 
Dox with transient transfection of CMV-GFP-N1ICD or CMV-GFP, TOPFlash 
firefly luciferase and CMV renilla luciferase plasmids. Bar graphs represent 
firefly luciferase luminescence normalized to renilla luciferase luminescence. 
Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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of increasing nuclear β-catenin and TOPFlash activity beyond that of either one alone. 
Furthermore, HCT 116 cells are known to contain wild type APC with a heterozygous activating 
mutation in β-catenin, while DLD-1 cells contain a truncating loss of function mutation in APC 
(Yang et al., 2006). This implies that if RBM3 were only acting through inhibition of GSK3β 
activity, then DLD-1 cells should show no significant upregulation of β-catenin activity and HCT 
116 should only show modest increases in β-catenin activity due to one allele containing the wild 
type β-catenin. However, our studies show that DLD-1-tRBM3 cells show a 1.7-fold change and 
HCT 116-tRBM3 cells an 8.6-fold increase in TOPFlash activity. These findings reveal that 
while RBM3 overexpression results in phosphorylation of GSK3β, thereby attenuating β-catenin 
degradation, this is only a partial mechanism and there is an as yet unknown role that RBM3 
plays in modulating β-catenin signaling.  
 
In both IHC for free overexpressed RBM3 and fluorescent microscopy for overexpressed GFP-
RBM3 fusion protein, we note that RBM3 is primarily localized within the nucleus. However, 
while the bulk of RBM3 appears to exist within the nucleus, it has also been observed to display 
nuclear-cytoplasmic shuttling activity (Sureban et al., 2008b). RBM3 has also been shown to be 
associated with the RNA binding protein HuR, a protein that has been shown to display direct 
protein-protein interaction with β-catenin (D'Uva et al., 2013; Kim et al., 2012b; Sureban et al., 
2008b). We propose, as a direction for further study, that RBM3 has either direct or indirect 
interaction with β-catenin protein and that its strong nuclear localization may serve as shuttling 
mechanism to further enhance nuclear translocation of cytoplasmic β-catenin. Additional studies 
are also required to determine whether RBM3 plays a role in β-catenin/TCF transcriptional 
activity. 
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Also of note is the correlation between hypoxia induction of RBM3 as previously described and 
the link between hypoxia and stem cells (Kaidi et al., 2007; Mazumdar et al., 2010; Wellmann et 
al., 2004; Yoshida et al., 2013). Although previous studies have reported that hypoxia is capable 
of affecting the stem cell population in various cancers, these studies focused on the HIF1α as 
the primary mechanism of modulating stem cell signaling pathways such as WNT/β-catenin 
(Kaidi et al., 2007; Mazumdar et al., 2010; Yoshida et al., 2013). Studies have demonstrated that 
hypoxia also suppresses GSK3β activity (Mottet et al., 2003). Our study demonstrates that 
increased RBM3 expression affects GSK3β activity thereby enhancing β-catenin signaling. As 
RBM3 is shown to be regulated by hypoxia in a HIF1α independent mechanism, this implies that 
RBM3 could be upstream of HIF1α or demonstrates a novel link between hypoxia and 
enrichment of stem cells. Furthermore, as GSK3β is important for controlling numerous biologic 
processes within the cell, it could be that altering RBM3 expression has far reaching 
consequences on the phenotype of the cell that remains to be elucidated. 
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Chapter IV: RBM3 induces a quiescent state in colon cancer cells 
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Introduction 
A major stressor of tissues within an organ is aging. Aging places a great demand on genomic 
integrity, telomere stability and long term viability. A potential mechanism by which intestinal 
epithelial renewal is maintained over the lifespan of an organism is through maintenance of 
cellular quiescence within a subset of stem cells allowing for decreased impact from the stress of 
aging. Cellular quiescence is the capability of exiting the cell cycle and remaining within a G0 
state with the capability to re-enter a cycling state depending upon the needs of the surrounding 
tissue. It has been demonstrated that the +4 LRC of the adult intestinal crypt maintains 
quiescence. +4 LRCs show remarkably long lived levels of nucleoside analog levels following 
pulse chase experiments giving rise to their name (Potten et al., 1978). Additionally +4 LRCs 
have been shown to be insensitive to loss of cell cycle regulators (Lee et al., 2009). However, 
these quiescent stem cells are able to regain the ability to divide following injury (Tian et al., 
2011).  
Interestingly, while the Wnt/β-catenin signaling pathway is normally associated with increased 
proliferation in cancer, it has also been shown to paradoxically maintain quiescence within the 
hepatocyte, myocyte and hematopoietic cells (Gougelet and Colnot, 2012; Povinelli and Nemeth, 
2014; Subramaniam et al., 2013). This complex interplay between Wnt induced proliferation and 
Wnt induced stem cell maintenance and its relevance in ISCs and colonic CSCs is as yet unclear.  
Important to note is that quiescence is one of the many mechanisms that CSCs utilize to subvert 
the effects of genotoxic chemotherapies. As most classical chemotherapies are designed to 
induce genotoxic insult to rapidly proliferating cells, quiescent CSCs often remain unaffected by 
these therapies. Recent studies have shown that hematopoietic and colonic CSCs display a 
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remarkable level of resistance to cytotoxic agents by entering a quiescent state (Cheng et al., 
2000; Dick, 2008; Touil et al., 2013). 
Here, we examine the phenotypic effect of RBM3 on cell cycle control. Specifically we show 
that overexpression of RBM3 generates decreased cell proliferation in colon cancer cells. 
Additionally, this decreased proliferation is maintained in vivo in tumor xenografts over long 
periods of time. Interestingly, RBM3 overexpression only yields minor changes in cell cycle 
progression. To further elucidate the effects of RBM3 on cellular quiescence, we use nucleotide 
analog labeling to show that RBM3 overexpression induces a marked increase in the percentage 
of quiescent cells. These results implicate yet another modality through which RBM3 may play a 
role in chemoresistance. 
 
Materials and Methods 
 
Cell culture 
HCT 116 cells were obtained from ATCC and cultured under conditions of 5% CO2 in DMEM 
(Corning) containing 10% FBS (Sigma-Aldrich) and 1% antibiotic/antimycotic solution 
(Corning). Following transduction of tGFP or tRBM3 virus, cells were cultured as mentioned 
above with additional 1 mg/mL G 418 (Santa Cruz Biotechnology) and 1µg/mL puromycin (Life 
Technologies). 
 
Western blotting 
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Western blot were performed using poly-acrylamide gel electrophoresis within a Miniprotean 
Tetracell apparatus (BioRad) followed by blotting onto 0.45µm pore size Immobilon polyvinyl 
difluoride membrane (Millipore) using a mini Transblot module (BioRad). Antibodies for 
p21CIP1/WAF1 were obtained from Cell Signaling (Cell Signaling Technology). 
 
Real time RT-PCR 
Total cellular RNA was isolated using TRIzol reagent followed by reverse transcription using 
SuperScript II in the presence of random hexonucleotide primers (Life Technologies). cDNA 
was then analyzed by real-time RT-PCR using Jumpstart Taq polymerase (Sigma Aldrich) and 
SYBR Green nucleic acid stain (Life Technologies). Threshold crossing values for each gene 
were normalized to glyceraldehyde phosphate dehydrogenase (GAPDH) gene expression. 
mRNA expression was then normalized to fold change relative to uninduced controls. Primers 
used in this study are as follows: 
p21CIP1/WAF1: 5’-CCATGTGGACCTGTCACTGT-3’ / 5’-
TGGTAGAAATCTGTCATGCTGGTC-3’ 
GAPDH: 5’-CAGCCTCAAGATCATCAGCA-3’ / 5’-GTCTTCTGGGTGGCAGTGAT-3’ 
 
Microarray analysis 
RNA was harvested using TRIzol (Life Technologies) according to manufacturer 
recommendations. Microarray analysis was performed using the Human Transcriptome Array 
2.0 (Affymetrix) according to manufacturer recommendations. Data were analyzed using 
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Transcriptome Analysis Console (Affymetrix). Results were screened for coding genes with 
FDR corrected P values less than 0.05. 
 
Proliferation assay 
Cells were plated at 50,000 cells per mL into 96 well plates and allowed to adhere overnight 
followed by treatment with indicated treatments. Following treatment for the indicated time, cells 
were assayed for proliferation using the hexoseaminidase assay as previously described 
(Subramaniam et al., 2008). Briefly, cell culture medium was removed followed by addition of 
75µL hexoseaminidase substrate buffer (7.5 mM sodium citrate, pH 5.0, 3.75 mM 4-nitrophenyl-
N-acetyl-β-D-glucosaminide, 0.25% Triton) per well and incubation at 37°C for 30 minutes. The 
reaction was quenched using 112.5 µL of hexoseaminidase developer solution (50 mM glycine, 5 
mM EDTA, pH 10.4) and absorbance at 405 nm was read on a plate reader. Percentage 
proliferation was calculated as absorbance relative to untreated control and curves for inhibitory 
response were fit using GraphPad Prism software (GraphPad). 
 
Spheroid formation assay 
Cells were appropriately treated in 2D culture, trypsinized followed by a wash in PBS to remove 
residual serum. Cells were then resuspended in spheroid media containing 1x B27 supplement, 
20 ng/mL bFGF and 20 ng/mL recombinant EGF (Life Technologies) in DMEM. Cells were 
passed through a 35 µm sieve, counted and plated onto ultra-low attachment surface plates 
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(Corning). Spheroid formation was allowed to proceed for 10-14 days followed by spheroid 
quantification and analysis using a Celigo Cyntellect embryoid body counter. 
 
Tumor Xenografts 
Cells were grown with 500 ng/mL Dox for 72 hours in 2D culture. Cells were then trypsinized 
and 1 million cells were injected suspended in PBS into the flanks of nude mice. Tumor 
formation was measured once per week using Vernier calipers for volume measurement. Volume 
was calculated as 
2
 
where L represents length and W represents width. If injection sites had no palpable tumor at 
time of measurement, tumor volume was recorded as 0 cm3. Mice were euthanized at 35 days 
and tumors were harvested and weighed.  
 
Cell Cycle 
Cells were plated and treated with indicated concentrations of Dox for 72 hours. Cells were then 
trypsinized, washed and fixed in 70% ethanol/30% PBS overnight. Fixed cells were then washed 
and stained in cell cycle staining buffer containing 1% propidium iodide (Life Technologies, 
Inc.) and 3% RNAseA (Sigma-Aldrich) in PBS and analyzed by flow cytometry. 
 
Quiescence assay 
167
 
Cellular quiescence was measured as previously described with minor alterations (Coller et al., 
2006). Cells were cultured at extremely low seeding density (35,000 cells/mL) in indicated 
concentrations of Dox. At 48 hours of induction, cells were given either normal culture medium 
with selection antibiotics or serum free culture medium with selection antibiotics and fresh Dox 
as appropriate. Serum deprivation was a positive control for induced quiescence. Following 72 
hours with appropriate Dox treatment, cells were treated with 100 µM bromo-deoxy uridine 
(BrdU). Cells were harvested with trypsin/EDTA, washed and fixed overnight at -20°C in 
fixation solution (70% ethanol, 50 mM glycine, pH 2.0). Nuclei were denatured using 4 M HCl 
treatment for 15 minutes followed by neutralization with PBS. Cells were then blocked for 30 
minutes (2% bovine serum albumin in PBS) and incubated for 1 hour at room temperature with 
alexafluor-488 (AF488) conjugated anti-BrdU antibody (Life Technologies). Cells were washed 
and resuspended in cell cycle staining solution containing 1% propidium iodide (Life 
Technologies, Inc.) and 3% RNAseA (Sigma-Aldrich) and analyzed by flow cytometry. 
 
Results 
We first observed that RBM3 overexpression induces significant chemoresistance against 
paclitaxel and modest chemoresistance against ADM (Chapter 2 Figures 15 & 16). Interestingly, 
the mechanism of action of paclitaxel is thought to be cell cycle specific while ADM is thought 
to be partially cell cycle non-specific (Pommier et al., 2010). We reasoned that RBM3 may 
confer multiple modalities of drug resistance with quiescence explaining the large difference 
between resistances in paclitaxel versus ADM. 
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We initiated these studies by investigating the effect on RBM3 overexpression in overall 
proliferation in HCT 116 tRBM3 cells. We observed that as expected, RBM3 overexpression in a 
dose and time dependent manner progressively decreases proliferation (Figure 1). This effect 
was replicated through RBM3 overexpression in a p53 null variant of HCT 116 (HCT 116p53-/-) 
(Figure 2). Both HCT 116 with wild type p53 and HCT 116p53-/- show decreased proliferation 
following Dox induction. The overall curves between the two cell lines differ somewhat but we 
attribute this to differences between RBM3 induction characteristics following transduction of 
the different cell lines. Interestingly, the cell cycle regulator p21CIP1/WAF1 showed a 
significant increase in our whole transcriptome analysis of RBM3 overexpressing HCT 116 cells 
(Table 1). p21CIP1/WAF1 is a downstream target of p53 and is necessary for maintaining HSCs 
in a quiescent state (Cheng et al., 2000; Porlan et al., 2013; van Os et al., 2007). We further 
validated the microarray finding by showing that RBM3 overexpression increases 
p21CIP1/WAF1 protein and mRNA significantly in HCT 116 tRBM3 cells with no appreciable 
change in vector control (Figure 3A). Interestingly, this effect was independent of inhibition of 
GSK3β using BIO implying that RBM3 overexpression induces an upregulation in 
p21CIP1/WAF1 independent of RBM3 induced β-catenin overactivation (Figure 3B).  
We next presumed that if RBM3 overexpression were to modulate the proliferative capacity of 
colon cancer cells, there may be an effect on the size of spheroid formation in vitro and tumor 
formation in vivo following RBM3 overexpression. We initially observed that RBM3 
overexpression confers increased capacity to form spheroids in ultra-low attachment conditions 
(Figure 4B). Interestingly though, while RBM3 overexpressing cells formed a greater number of 
spheroids, the average diameter of the spheroids formed was smaller than that of uninduced 
controls (Figure 4A). Additionally, following 72 hours of induction with 500 ng/mL of Dox, 
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Figure 1: RBM3 overexpression decreases proliferation in a dose dependent 
manner. Hexoseaminidase proliferation assay following treatment with Dox 
showing that RBM3 overexpression decreases proliferation at 48 hours and 72 
hours of induction. Proliferation of GFP overexpressing cells remains largely 
unchanged. Error bars represent SEM. 
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Figure 2: RBM3 induced decreases in proliferation are independent of p53. 
Hexoseaminidase proliferation assay following treatment for 48 hours with Dox 
showing that RBM3 overexpression decreases proliferation in HCT 116 cells 
with wild type p53 or p53 knockout. Error bars represent SEM. 
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Figure 3
Gene  
Symbol Description 
Fold 
Change 
FDR  
p-value 
CPA4 carboxypeptidase A4 8.73 0.0356 
IL8 interleukin 8 2.24 0.0298 
TMPRSS11E transmembrane protease, serine 11E 2.12 0.0326 
DUSP5 dual specificity phosphatase 5 2.07 0.0298 
RNU6ATAC RNA, U6atac small nuclear  2.01 0.0495 
CTGF connective tissue growth factor 1.95 0.0437 
EMP1 epithelial membrane protein 1 1.84 0.0479 
GJB3 gap junction protein, beta 3, 31kDa 1.71 0.0368 
SLAMF7 SLAM family member 7 1.67 0.0298 
PLK3 polo-like kinase 3 1.64 0.0430 
EPHA2 EPH receptor A2 1.61 0.0298 
FLNC filamin C, gamma 1.58 0.0368 
MYC v-myc myelocytomatosis viral oncogene homolog 1.54 0.0469 
FHL2 four and a half LIM domains 2 1.53 0.0298 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.48 0.0401 
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Table 1: Representative table of RBM3 induced genes. The table is a selected list 
of genes upregulated in HCT 116-tRBM3 cells compared to HCT 116-tGFP cells 
following 72 hours of induction with 500 ng/mL Dox. mRNA was harvested and 
analyzed using Human Transcriptome Microarray 2.0 analysis. Shown in bold are 
genes validated in this study. P values are obtained using ANOVA with false 
discovery rate correction. 
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Figure 3: RBM3 overexpression increases p21 expression. (A) Western blot 
analysis of p21CIP1/WAF1 following RBM3 induction with 500 ng/mL Dox for 
72 hours showing a significant increase in p21 levels with RBM3 overexpression. 
(B) Real time RT-PCR of p21CIP1/WAF1 following Dox induction for 72 hours. 
(C) Western blot analysis of p21CIP1/WAF1 following treatment with 500 
ng/mL Dox or 100 nM BIO for 72 hours showing a significant increase in p21 
levels with RBM3 overexpression but not BIO treatment. Bar graphs represent 
fold change relative to control. Error bars represent SEM. P values shown are 
obtained with Student’s t-test. Densitometry represents fold change of p21 
relative to uninduced tRBM3 cells normalized to GAPDH. Error represents SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). 
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Figure 4: RBM3 overexpressing spheroids are greater in number but smaller in 
size. (A) Quantification of average spheroid diameter as performed by Celligo 
embryoid body counting system. Cells were grown in monolayer culture for 72 
hours with inidicated Dox concentration then grown as spheroids for 14 days. Bar 
graph shows average of the average spheroid diameter of each sample. (B) 
Quantification of average spheroid number following RBM3 induction. Bar graph 
shows spheroid number from 2,500 seeded cells. Error bars represent SEM. P 
values shown are obtained with Student’s t-test.  
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Figure 5: RBM3 overexpression decreases proliferation in tumor xenografts. (A) 
Tumor xenograft volume measured at 35 days. HCT 116 tGFP and tRBM3 cells 
were grown in 500 ng/mL Dox for 72 hours then injected into the flanks of nude 
mice. (B) Tumor xenograft size of HCT 116 cells injected into the flanks of nude 
mice. (C) Images of xenografts collected from mice following 35 days of growth. 
Scale bar represents 1 cm.  
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HCT 116 tRBM3 or tGFP cells were injected into the flanks of nude mice to assess tumor 
xenograft formation. We observed that RBM3 overexpression compared to GFP overexpression 
generated tumors of decreased size over time and decreased weight following 35 days of tumor 
formation (Figure 5). This implies that RBM3 decreases cell proliferation in vitro and in vivo. 
We next investigated how RBM3 overexpression alters cell cycle progression. As no significant 
proliferative changes were observed in HCT 116 tGFP cells following Dox induction, we opted 
not to investigate cell cycle progression on these cells. We analyzed the cell cycle profile of 
RBM3 overexpressing HCT 116 tRBM3 cells following 72 hours of induction. Interestingly, 
RBM3 overexpression generated modest increases in the G0/G1 phase (Figure 6). To further 
elucidate the effects of RBM3 induction on progression through cell cycle, we used a method 
established by Coller, et al. to discriminate G0 from G1 phase. Treatment with the nucleoside 
analog BrdU was initiated for 6 hours following 72 hours of RBM3 induction so that only cells 
which have actively cycled over the past 6 hours will have BrdU incorporated into DNA. Serum 
starvation was used as a positive control for quiescence. Following 6 hours of BrdU treatment, 
we observed that RBM3 overexpressing cells had significantly higher levels of quiescent cells 
and far fewer actively cycling cells (Figure 7). Additionally, DLD-1-tRBM3 cells also showed 
an increase of quiescent cells with a corresponding decrease in the percentage of cycling cells 
(Figure 8). 
 
Discussion 
Here we show evidence implicating RBM3 in the induction of a quiescent phenotype. It should 
be noted that previous studies have shown that loss of RBM3 through siRNA mediated 
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Figure 6: RBM3 overexpression induces accumulation of cells at G0/G1 phase. 
Cell cycle analysis histograms showing that RBM3 overexpressing cells show 
modest accumulation at G0/G1 phase. Cells were induced with indicated 
concentrations of Dox for 72 hours then had DNA stained using PI. Cells were 
then analyzed by flow cytometry for cell cycle. Histogram represents whole and 
single cells. 
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Figure 7: RBM3 overexpression increases quiescence in HCT 116 tRBM3 cells. 
Cells were induced with indicated concentrations of Dox for 72 hours then treated 
with BrdU for 6 hours. Cells were then stained for BrdU uptake (AF488). 
Cycling cells (blue) represent fraction of cells which take up BrdU over 6 hours, 
quiescent cells (red) represent cells which take up no BrdU over 6 hours. Bar 
graph shows percentage of gated cells. Serum deprivation is used as a positive 
control for quiescence. 
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Figure 8: RBM3 overexpression increases quiescence in DLD-1 tRBM3 cells. 
Cells were induced with indicated concentrations of Dox for 72 hours then treated 
with BrdU for 6 hours. Cells were then stained for BrdU uptake (AF488).Cycling 
cells (blue) represent fraction of cells which take up BrdU over 6 hours, quiescent 
cells (red) represent cells which take up no BrdU over 6 hours. Bar graph shows 
percentage of gated cells. Serum deprivation is used as a positive control for 
quiescence. 
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knockdown results in cells undergoing mitotic catastrophe (Sureban et al., 2008b). Mitotic 
catastrophe is a phenomenon where cells enter the G2/M phase of cell cycle promiscuously and 
undergo apoptosis. This implies that the levels of RBM3 show a dose dependent correlation with 
the overall levels of proliferation and cell cycle progression and that RBM3 could be heavily 
involved in cell cycle regulation.  
While the mechanism behind RBM3 induced quiescence is still unclear, it is possible that RBM3 
directly regulates p21CIP1/WAF1, a cell cycle regulatory protein that is critical for inducing 
quiescence (Cheng et al., 2000; Porlan et al., 2013; van Os et al., 2007). p21CIP1/WAF1 also 
plays a role in halting cell cycle progression to allow for DNA repair, thereby increasing 
resistance to genotoxic insults (Abbas and Dutta, 2009). Additionally, it appears that the RBM3 
induced quiescent phenotype persists in the absence of p53 further implicated a direct interaction 
between RBM3 and p21CIP1/WAF1. It is interesting to observe that RBM3 induced quiescence 
appears independent of p53. However, p21 a downstream target of p53 is induced implying that 
RBM3 may alter p21 levels at the post-transcriptional level (Beckerman and Prives, 2010). This 
theory is not without precedent. Previous studies have shown that the RNA binding protein HuR 
shares similar mRNA binding clients as RBM3 and both seem to have affinity towards AU-rich 
sequence elements (Sureban et al., 2008b; Young et al., 2009). Notably, one study has shown 
that following stress conditions, HuR can bind to p21CIP1/WAF1 mRNA and increase mRNA 
half-life and protein levels (Wang et al., 2000). As RBM3 seems to upregulate p21CIP1/WAF1 
expression, it is possible that RBM3 overexpression alters mRNA stability or translation rate of 
p21CIP1/WAF1 to induce cellular quiescence.  
We also note that in the previous chapter, we showed that RBM3 overexpression can generate an 
increase in the migratory phenotype in HCT 116 cells (Chapter 3, Figure 6). It has been 
189
 
previously demonstrated that nuclear β-catenin levels are highly correlative with invasiveness 
(Brabletz et al., 1998). Interestingly, these invasive cells also show a decrease in proliferative 
index implying that the invasiveness program is also associated with quiescence (Jung et al., 
2001). However, as RBM3 induced p21CIP1/WAF1 expression is not phenocopied by BIO 
treatment to overeactivate β-catenin, it may be that RBM3 induced β-catenin activation and 
quiescence may be independent effects which may act in parallel to accentuate certain 
phenotypes such as invasion and migration. Taken together, our findings indicating that RBM3 
overexpression increases both invasiveness and quiescence implies that RBM3 induction may be 
associated with more phenotypic characteristics that have yet to be observed. 
Hypoxia has also been shown to induce quiescence in a HIF-1α dependent manner (Takubo et 
al., 2010). It is possible that RBM3 is also involved in hypoxia induced quiescence either acting 
through HIF-1α regulation or in parallel with it. It is reasonable to infer that because RBM3 
generates protective effects to stressors such as hypoxia, cold shock and serum deprivation, it 
may play a role in inducing quiescence to preserve cell function in a nutrient deprived 
environment through decreased cellular activity and nutrient consumption. By doing so, RBM3 
may serve as a double edged sword which decreases proliferation of a tumor, but increases its 
resistance to genotoxic therapies. It would be interesting to investigate if siRNA mediated knock 
down of p21CIP1/WAF1 could attenuate the RBM3 mediated chemoresistance to cell cycle 
specific therapies such a paclitaxel. Further studies are needed to validate this idea. 
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Chapter V: Conclusions and Significance 
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The intestinal epithelium is one of the fastest renewing tissues within the adult. This renewal is 
driven by the proliferation of a transit amplifying compartment which is in turn derived from 
stem cells residing within the intestinal crypts. The homeostasis of the ISC compartment needs to 
be tightly regulated and loss of this regulation often leads to the formation of malignant 
neoplasia. These transformed adenomas and adenocarcinomas harbor a small CSC population 
that displays characteristics implicating more aggressive disease such as tumor initiation capacity 
and multidrug resistance. A thorough understanding of the mechanisms that govern the behavior 
of the CSC pool may lead to more effective therapies for combating colon cancer. 
The β-catenin signaling cascade is a critical pathway involved in the maintenance of self-renewal 
in the ISC (Brabletz et al., 2009; Burgess et al., 2011; Medema and Vermeulen, 2011; van der 
Flier and Clevers, 2009). Loss of regulation of β-catenin signaling, either through truncating 
mutation of APC or overactivating mutation of β-catenin, has been shown to be present in the 
majority of colon cancers implicating it as the initiating step in neoplastic transformation (Fearon 
and Vogelstein, 1990; Groden et al., 1991; Kinzler and Vogelstein, 1997; Morin et al., 1997; 
Moser et al., 1990). Moreover, knocking out the tumor suppressor Apc in ISCs compared to 
epithelium fated to terminally differentiate, results in a more profound tumorigenesis in the 
mouse intestine (Barker et al., 2009). This overactivation of β-catenin has been implicated in the 
progression of colon cancers by increasing characteristics such as invasiveness and 
chemoresistance (Brabletz et al., 2009; Kanwar et al., 2010). 
The RNA binding protein RBM3 has been shown to induce oncogenic transformation in vitro 
and has been shown to be a necessary component in the maintenance of tumor xenografts in vivo 
(Sureban et al., 2008b). RBM3 has been shown to be upregulated as neoplasias progress to 
higher stages in astrocytoma, colon and prostate cancer implicating significant correlation 
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between RBM3 expression and cancer aggressiveness (Shaikhibrahim et al., 2013; Sureban et al., 
2008b; Zhang et al., 2013). In prostate cancer, it has also been shown to be an independent 
prognostic factor linked to increased chemical recurrence and decreased overall survival (Grupp 
et al., 2013). RBM3 also appears to be closely related to stem cells as it is observed to be 
upregulated in HSC (Baghdoyan et al., 2000). Moreover, similar to CSCs being enriched in 
hypoxic environments, RBM3 is induced by hypoxia (Wellmann et al., 2004). However, these 
studies fall short in examining the exact causative role of RBM3 in modulating the behavior of 
cancers in general and more specifically CSCs. 
In this study, we investigated the link between RBM3 and the colon CSC. We initiated these 
studies by validating that exogenous RBM3 overexpression increased the percentage of cells that 
behave with stem cell characteristics. We verified this using two separate functional assays as 
well as measuring changes in the expression of putative stem cell markers. As a secondary 
consequence of the stem cell phenotype, we showed that RBM3 overexpression generates 
chemoresistance through the upregulation of multidrug efflux activity. We went on to 
demonstrate that RBM3 is capable of modulating the β-catenin signaling pathway through 
alteration of GSK3β activity and implicated the PI3K-AKT axis as a potential mechanistic 
explanation. Finally, we investigated a paradoxical effect of RBM3 overexpression which 
induces the phenotype of quiescence, a primary characteristic of CSCs and an additional 
mechanism of chemoresistance. The findings presented here further our understanding of the 
factors that govern stem cell behavior by demonstrating a novel role for RBM3 in modulating the 
population colon CSC population. Additionally these findings present new avenues to explore 
for predicting and potentially overcoming recurrences and chemotherapy refractory malignant 
neoplasias.  
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Chapter II: Overexpression of RBM3 increases stem cell characteristics and chemoresistance in 
colon cancer cells  
Previous studies have demonstrated that RBM3 is overexpressed in neoplastic tissue compared to 
normal adjacent controls (Grupp et al., 2013; Shaikhibrahim et al., 2013; Sureban et al., 2008b; 
Zhang et al., 2013). To establish a causative link between RBM3 and cancer, we exogenously 
overexpressed RBM3 in HCT 116 and DLD-1 colon cancer cells and characterized the 
expression kinetics with the Dox inducible system.  
First, we showed that Dox induction of RBM3 induced an increase in the SP percentage in both 
DLD-1 and HCT 116 cells implying that RBM3 overexpression generates an increased 
population of cells with efflux capacity. We validated this finding by demonstrating that RBM3 
overexpression results in decreased ADM uptake and increased ADM efflux in HCT 116 cells 
and that this efflux appears to be largely attributed to a small subset of cells. This was consistent 
with our finding that RBM3 induction also generated an increase in mRNA transcripts for MRP2 
and Pgp efflux transporters. This is finally confirmed by the finding that RBM3 overexpressing 
cells are resistant to treatment with paclitaxel and ADM which are substrates of Pgp and MRP2. 
Second, we showed that RBM3 overexpression generated an increase in spheroid formation 
capacity in both DLD-1 and HCT 116 cells. As spheroid formation capacity is an in vitro marker 
of “stemness”, this further confirmed that RBM3 induces a stem cell phenotype. Finally, we 
showed that RBM3 overexpression increased the percentage of cells with expression of the 
putative stem cell markers DCLK1, LGR5 and CD44. 
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Taken together, we conclude that RBM3 overexpression increases the percentage of stem-like 
cells within a given population of colon cancer cells and that this is correlated with an increase in 
resistance to classical chemotherapies through increase of efflux. This implies that the increased 
expression of RBM3 that has been observed in various solid tumors may serve a role in altering 
the regulation of the CSC population to generate a more aggressive and more chemoresistant 
tumor. 
 
Chapter III: RBM3 overexpression generates an increase in β-catenin signaling 
β-catenin signaling is a critical pathway for colon CSCs and is also known to drive transcription 
of LGR5 and CD44 mRNA (Barker et al., 2007; Kanwar et al., 2010; Wielenga et al., 1999). To 
establish a potential signaling mechanism through which RBM3 overexpression may generate an 
increased stem cell phenotype, we overexpressed RBM3 in HCT 116 and DLD-1 cells and 
measured changes in β-catenin activity. 
We observed that RBM3 overexpression in both DLD-1 and HCT 116 cell lines resulted in a 
significant increase in total and nuclear β-catenin levels with no significant changes in 
cytoplasmic β-catenin levels. This was validated through IF and IHC staining of RBM3 
overexpressing cells demonstrating that cells with high levels of nuclear RBM3 also had 
increased nuclear localization of β-catenin. We also observed that prolonged overexpression of 
RBM3 generated an increase in wound healing capacity, a known phenotype of β-catenin 
induced EMT. We also validated that this RBM3- induced upregulation in nuclear β-catenin 
results in increased transcriptional activity by demonstrating higher levels of c-MYC, LGR5 and 
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CD44 mRNA. Moreover, we showed that RBM3 overexpression increases TOPFlash luciferase 
reporter activity in both DLD-1 and HCT 116 cells.  
To elucidate a potential molecular mechanism for this RBM3 induced β-catenin activity, we 
showed that RBM3 overexpression results in increased AKT activity and a decreased GSK3β 
activity. In confirmation of this, we showed that pharmacologic inhibition of GSK3β using BIO 
was capable of phenocopying the RBM3 induced β-catenin activity as measured by nuclear β-
catenin and TOPFlash activity. Interestingly however, we also observed that concurrent RBM3 
overexpression and pharmacologic GSK3β inhibition using BIO further increases β-catenin 
activity implying a second molecular mechanism. 
Taken together, we conclude from these studies that RBM3 overexpression is a novel regulatory 
factor of the β-catenin signaling cascade. While further studies are needed to further understand 
the mechanism of RBM3 action, we implicate the enhanced β-catenin activity as a causative 
mechanism in the increases observed in stem cell phenotype following RBM3 induction.  
 
Chapter IV: RBM3 induces a quiescent state in colon cancer cells 
Quiescence is a hallmark of physiologic ISCs as well as CSCs (Borst, 2012; Buczacki et al., 
2011; Dick, 2008; Li and Bhatia, 2011; Touil et al., 2013). Furthermore, Wnt/β-catenin signaling 
has been heavily implicated in self-renewal and quiescence for long term maintenance of HSCs 
(Fleming et al., 2008; Nemeth et al., 2009; Povinelli and Nemeth, 2014). Our previous studies 
demonstrated RBM3 overexpression increases β-catenin signaling and the CSC population in 
HCT 116 and DLD-1 colon cancer cells. 
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Here, we showed that RBM3 overexpression generates a decrease in cell proliferation. This was 
observed in both monolayer and spheroid cultures. Additionally, we observed a decrease in 
proliferation in tumor xenografts. This decrease in proliferation appears independent of p53 
status. However, RBM3 overexpression did induce an upregulation in the cell cycle control 
protein p21CIP1/WAF1. Moreover, RBM3 overexpression generated modest accumulation of 
cells at the G0/G1 phase. Upon resolution of G0 and G1 phases using nucleotide uptake and flow 
cytometric analysis, we observed that this accumulation appears to be predominantly within the 
G0 phase. These findings are consistent with earlier findings of RBM3 induced chemoresistance 
as cellular quiescence is an established mechanism for inducing resistance in CSCs. 
Taken together, we conclude that RBM3 induces decreased cellular proliferation in colon cancer 
cells which is primarily attributed to cellular quiescence and that this may be an additional 
mechanism of RBM3 induced chemoresistance. As previous studies have also shown that loss of 
RBM3 is associated with premature entry into cell cycle followed by apoptosis, we infer that 
RBM3 may play a central role in cell cycle regulation (Sureban et al., 2008b). 
 
Significance 
Previous studies have shown that RBM3 appears to be capable of inducing oncogenic 
transformation and that it is correlated with increased aggressiveness. To our knowledge, we are 
the first to show causative evidence of RBM3 in the initiation and progression of colon cancer. 
We demonstrate that RBM3 can induce a CSC phenotype which is thought to be the tumor 
initiating population. Additionally, we show that RBM3 is a novel factor capable of modulating 
β-catenin signaling activity, a pathway critical to initiation and progression of colon cancer. 
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These findings further our understanding of the mechanisms that govern the behavior of tumors, 
specifically the subpopulation of CSCs. With additional research, these findings may have 
tremendous clinical implications as well. The finding that RBM3 induces resistance to 
chemotherapies indicates the potential for RBM3 to be used as a predictive marker to evaluate 
responsiveness to various chemotherapies. Moreover, it may well be a new molecular target to 
exploit as a treatment strategy for colon cancers. 
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